Section 36

EurekaMag PDF full texts Chapter 35,456


Tappia, P.S.; Maddaford, T.G.; Hurtado, C.; Dibrov, E.; Austria, J.A.; Panagia, V.; Pierce, G.N. 2001: PLC/IP3 signaling defects underly abnormal contractile activity induced by phosphatidic acid in diabetic rat cardiomyocytes. Journal of Molecular and Cellular Cardiology 33(6): A120
Moepps, B.; Tulone, R.; Heber, C.; Wieland, T.; Gierschik, P. 2004: PLCO-independent activation of Rho GTPases by a constitutively active, Gq-coupled viral chemokine receptor homologue. Naunyn-Schmiedeberg's Archives of Pharmacology 369(Suppl 1): R50
Lian, L.; Wang, Y.; Bach, T.L.; Eslin, D.E.; Wu, D.; Bennett, J.S.; Poncz, M.; Abrams, C.S. 2003: PLCbeta2/beta3 and PI3Kgamma and are both required for ex vivo and in vivo platelet function. Blood 102(11): 773a
Kashiwadani, H.; Miyata, M.; Kawakami, Y. 2003: PLCbeta4 modulates the response of VPL neurons to inflammatory pain. Neuroscience Research Suppl (26): S82
Sorbera, L.A.; Castaner, J.; Bozzo, J. 2002: PLD-118 Antifungal, isoleucyl-tRNA synthetase inhibitor. Drugs of the Future 27(11): 1049-1055
Schroedter, A.; Bischoff, A.; Oreskovic, K.; Knoeller, J.; Schoenfeld, W.; Peterson, J. 2002: PLD-118 Tolerability, safety and pharmacokinetics after multiple oral dosing in healthy male volunteers. Mycoses 45(Suppl 2): 54-55
Touyz, R.M.; Schiffrin, E.L. 2000: PLD-dependent generation of oxygen species is increased in Ang II-stimulated vascular smooth muscle cells from hypertensive patients. American Journal of Hypertension 13(4 Part 2): 153A-154A
Powner, D.J.; Hodgkin, M.; Wakelam, M.J.O. 2001: PLD1b is activated by Rac1, ARF6 and PKCalpha in RBL-2H3 cells. Biochemical Society Transactions 29(3): A82
Alonso Lebrero, J.L.; Gil, J.C.; Pivel, J.P. 2003: PLE impairs ultraviolet B-induced immunosuppression in a hypersensitivity assay. Inflammation Research 52(Suppl 2): S 136
Flores-Perez,U.; Perez-Gil,J.; Closa,M.; Wright,L.P.; Botella-Pavia,P.; Phillips,M.A.; Ferrer,A.; Gershenzon,J.; Rodriguez-Concepcion,M. 2010: Pleiotropic Regulatory Locus 1 Integrates the Regulation of Sugar Responses with Isoprenoid Metabolism in Arabidopsis. Molecular Plant: 1, 101-112
Samuel, J. 2003: PLGA nanosphere delivery of peptides and lipopeptides to dendritic cells. Cancer Immunology Immunotherapy 52(Suppl 1): S29
Rickerby, J.; Prabhakar, R.L.; Knowles, J.C.; Brocchini, S. 2003: PLGA surrogate polymer libraries. Journal of Pharmacy and Pharmacology 55(Suppl): S 22
Singh, J.; Somavarapu, S.; Alpar, H.O. 2003: PLGA-PCL-co-polymer nanoparticles as a vaccine delivery system. Journal of Pharmacy and Pharmacology 55(Suppl): S 56
Sheridan, A.M.; Force, T.; Sapirstein, A.; Bonventre, J.V. 1999: PLIP increases TNFalpha-induced COX-2 expression and has in vitro histone acetyltransferase activity. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 471A
Sheridan, A.M.; Yoon, H.J.; Force, T.; Bonventre, J.V. 2000: PLIP increases serum deprivation-induced apoptosis and PGE2 production in cPLA2+/+ but not cPLA2-/- mouse mesangial cells. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 436A
Sheridan, A.M.; Force, T.; Sapirstein, A.; Bonventre, J.V. 1999: PLIP, a novel cPLA2-interacting protein, increases apoptosis induced by serum deprivation and by TNFalpha, enhances TNFalpha-induced COX-2 expression and has in vitro histon acetylase transferase activity. Prostaglandins and Other Lipid Mediators 59(1-6): 122
Knecht, R.; Oberhauser, C.; Strebhardt, K. 2000: PLK , a new prognostic marker for oropharyngeal carcinomas. International Journal of Cancer 89(6): 535-536, 20 November
Griebe, M.; Jaeger, T.M.; Wolf, G.; Bleyl, U.; Grobholz, R. 2001: PLK in prostatic carcinoma Influence of neuroendocrine tumor cells on proliferation. Journal of Cancer Research and Clinical Oncology 127(Suppl 1): S41
Fantini, L.; Michaud, M.; Gosselin, N.; Montplaisir, J. 2001: PLMS and autonomic activation in patients with restless legs syndrome and REM sleep behavior disorder. Sleep 24(Abstract Suppl): A360-A361
Boucher, S.E.M.; Carlock, L.R.; Skoff, R.P. 2000: PLP gene modulates neuron viability and morphology. Journal of Neurochemistry 74(Suppl ): S31
Shy, M.E.; Garbern, J.; Mancias, P.; Lewis, R.A.; Kamholz, J. 2000: PLP neuropathies Proving the null hypothesis. Neurology 54(7 Supp 3): A70
Zhang, S.; Kashii, S.; Mandai, M.; Yasuyoshi, H.; Miyamoto, N.; Yamauti, T.; Honda, Y.; Kume, T.; Akaike, A. 2000: PLP protects cultured retinal neurons from glutamate-induced neurotoxicity by suppression of nitric oxide synthase. IOVS Investigative Ophthalmology and Visual Science 41(4): S186
Hwang, I.T.; Chun, J.Y. 2001: PLP-Cg, a novel member of the prolactin-like protein-C subfamily, produces two alternatively spliced forms. Developmental Biology 235(1): 243
Zhang, L.; Wang, T.; Maumenee, I.H.; Valle, D. 2003: PLP2, a novel candidate gene for X-linked retinitis pigmentosa. American Journal of Human Genetics 73(5): 169
Davis, T.A.; Wannberg, S.L.; Tuse, D. 2002: PLURIGENTM CM Supports the Ex Vivo Expansion of Primitive Human Hematopoietic Cells Capable of Repopulating Immune-Deficient Mice. Blood 100(11): Abstract No. 5179
Costoya, J.A.; Piazza, F.; Barna, M.; Cattoretti, G.; Pandolfi, P.P.olo 2002: PLZF Controls the Homeostasis of the Hemopoietic Stem Cell Compartment. Blood 100(11): Abstract No. 4115
Barna, M.; Merghoub, T.; Costoya, J.A.; Ruggero, D.; Branford, M.; Pandolfi, P.P.olo 2002: PLZF Mediates Transcriptional Repression of Hox Gene Expression through Chromatin Remodeling and Recruitment of Polycomb Proteins. Blood 100(11): Abstract No. 224
Yamasaki, K.; Dai, X.; Nanba, D.; Shiraishi, K.; Yahata, Y.; Tokumaru, S.; Tohyama, M.; Shirakata, Y.; Sayama, K.; Higashiyama, S.; Hashimoto, K. 2003: PLZF regulates and suppresses melanoma proliferation and tumor growth. Journal of Investigative Dermatology 121(1): 0190
Lieschke, G.J.; Pandolfi, P.P.; Varma, S. 2002: PLZF-RARalpha Transgenic Mice Lacking G-CSF, but Not Those Lacking GM-CSF, Fail To Develop Lethal Acute Myeloid Leukemia and Live a Normal Lifespan. Blood 100(11): Abstract No. 707
Mizutani, T. 2003: PM frequencies of major CYPs in Asians and Caucasians. Drug Metabolism Reviews 35(2-3): 99-106
Alfaro Moreno, E.; Heng, Y.M.; Edgson, J.; Symonds, P.; Osornio Vargas, A.; Rosas, I.; Murray, J.C.ifford 2003: PM10 effect on EMAP-II expression in lung epithelial cells. Toxicology Letters (Shannon) 144(Suppl 1): s106
Alfaro Moreno, E.; Heng, Y.M.; Osornio Vargas, A.; Rosas, I.; Murray, J.C.ifford 2003: PM10 effects on pro-inflammatory gene expression in lung epithelial cells. Toxicology Letters (Shannon) 144(Suppl 1): s183
Cyrys, J.; Dietrich, G.; Kreyling, W.; Tuch, T.; Heinrich, J. 2001: PM25 measurements in ambient aerosol Comparison between Harvard impactor and the tapered element oscillating microbalance system. Science of the Total Environment 278(1-3): 191-197, 20 October
Kruth, H.S.; Huang, W.; Ishii, I.; Zhang, W.Y.ng 2002: PMA activation of macrophages stimulates LDL uptake and foam cell formation. Journal of Interferon and Cytokine Research 22(Suppl 1): S-198
Decoursey, T.E.; Cherny, V.V.; Zhou, W.; Thomas, L.L. 2000: PMA enhances proton currents during the respiratory burst in human neutrophils. Biophysical Journal 78(1 Part 2): 131A
Mueller, R.; Junge, I.; Lattke, H.; Kaufmann, D. 1999: PMA increases neurofibromin half-life and its phosphorylation in cultured melanocytes. European Journal of Cell Biology 78(Suppl 49): 109
Dayton, M.A.; Smith, M.T. 2000: PMA induced changes in the expression of phosphotyrosine phosphatases during the differentiation of the CML cell line K562. Proceedings of the American Association for Cancer Research Annual Meeting 41: 140-141
Weller, S.G.; Penington, R.C.; Karnes, W.E. 2000: PMA induces apoptosis in the SNU-C4 colon cancer cells through caspase-9 independently of caspase-3 and -8. Gastroenterology 118(4 Suppl 2 Pt 1): AGA A542-AGA A543
Kruth, H.S.; Huang, W.; Zhang, W.Y.; Ishii, I. 2001: PMA inhibits plasmin-mediated release of aggregated LDL from macrophages. Journal of Leukocyte Biology Suppl: 40
Ho, J.J.L.; Farrelly, E.R.; Kim, Y.S. 1999: PMA reduces EGF induced tyrosine phosphorylation of EGF receptor in pancreatic cancer cells. Gastroenterology 116(4 Part 2): A1134
Garcia Ferreiro, R.E.; Hernandez Ochoa, E.O.; Garcia, D.E. 2000: PMA selectively prevents voltage-dependent inhibition of N-type calcium currents induced by G-protein activation. Biophysical Journal 78(1 Part 2): 105A
Malakooti, J.; Memark, V.C.; Li, X.; Dudeja, P.K.; Ramaswamy, K. 2002: PMA stimulation of the human NHE-2 promoter is PKC independent. Gastroenterology 122(4 Suppl 1): A 540
Falin, R.A.; Cotton, C.U. 2003: PMA-induced inhibition of amiloride-sensitive sodium absorption is partially mediated by ERK1/2 activation. FASEB Journal 17(4-5): Abstract 585
Ray, A.; Chen, J.; Murphy, R.; Ray, B.K. 2001: PMA-mediated signal transduction phosphorylates and activates transcription factor SAF in synovial fibroblast cells. FASEB Journal 15(4): A205
Backstrom, K.C.; Bertone, A.L.; Wisner, E.R.; Weisbrode, S.E. 2000: PMAT-1 gene activated matrix stimulates diaphyseal but not osteochondral bone healing in horses. Veterinary Surgery 29(5): 457
Thompson, E.W.; Fridman, M.; Ackland, L.; Price, J.T.; Arvanitis, A.; Waltham, M.; Minichiello, J.; Newgreen, D.F. 2002: PMC-42 human mammary carcinoma cells A model system for the analysis of EGF-induced epithelio-mesenchymal transition. Clinical and Experimental Metastasis 19(Suppl): 20
Kruglikov, I.; Shutov, L.; Fedirko, N.; Kostyuk, P.; Voitenko, N. 2003: PMCA and SERCA contribute to alteration of Ca2+ homeostasis in rat DH neurons under diabetic neuropathy. Biophysical Journal 84(2 Part 2): 389a-390a
Liu, L.; Okunade, G.; Ishida, Y.; Wachterman, J.; Shull, G.E.; Paul, R.J. 2004: PMCA isoforms and bladder contractility evidence from PMCA gene targeted mice. FASEB Journal 18(4-5): Abstract 699
Pyne, G.J.; Okunade, G.N.; Shull, G.E.; Paul, R.J. 2003: PMCA4 calcium pump knockout mice altered calcium handling but normal contractility in urinary bladders. FASEB Journal 17(4-5): Abstract
Xu, L.L.; Srikantan, V.; Shi, Y.; Sesterhenn, I.A.; Mcleod, D.G.; Moul, J.W.; Srivastava, S. 2002: PMEPA1, an androgen regulated gene, with growth inhibitory function in prostate cancer cells. Journal of Urology 167(4 Suppl): 55
Bernassola, Francesca; Salomoni, Paolo; Di Como, Charles; Pagano, Michele; Melino, Gerry; Pandolfi, Pier Paolo 2002: PML Enhances p73 Transcriptional Activity and Biological Functions by Preventing Its Proteasome-Dependent Degradation. Blood 100(11): Abstract No. 4210
Li, H.; Chen, J.D. 2000: PML and the oncogenic nuclear domains in regulating transcriptional repression. Current Opinion in Cell Biology 12(5): 641-644
Soussi, T.; De The, N. 1999: PML gene Oncogene. Bulletin du Cancer 86(2): 133
Chen, Guo Qiang 2002: PML gene, arsenic and apoptosis of leukemic cells. Cell Research 12(3-4): 288-289
Wu, W.S.; Meng, F.; Pandolfi, P.P.; Chang, K.S. 2001: PML growth-suppressor potentiates cell death through the inhibition of NF-kappa B survival pathway. FASEB Journal 15(4): A21
Baumann, C.T.; Reyes, J.C.; Lim, C.S.; Hager, G.L. 1999: PML localizes with GRIP-1 and functions in glucocorticoid receptor-dependent transcription. FASEB Journal 13(7): A1374
Dellaire, G.; Bazett-Jones, D.P. 2004: PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays: News and Reviews in Molecular Cellular and Developmental Biology 26(9): 963-977
Yu, E.; Yoon, G.S.; Lee, I. 1999: PML protein in hepatocellular carcinomas. Modern Pathology 12(1): 170A
Cabrera, C.M.; Cabrera, T.; Jimenez, P.; Garrido, F.; Ruiz Cabello, F. 2003: PML staining patterns in colorectal tumors with total loss of HLA class I. Genes and Immunity 4(Suppl 1): S40
Tomita, A.; Buchholz, D.R.; Shi, Y.B. 2003: PML-RAR and PLZF-RAR fusion proteins repress transcription by recruiting N-CoR-TBLR1 co-repressor complexes to target promoters in vivo. Blood 102(11): 590a-591a
Lane, A.A.; Westervelt, P.; Ley, T.J. 2002: PML-RARalpha Kills U937 Cells A Novel Activity of PML-RARalpha That May Contribute to APL Pathogenesis. Blood 100(11): Abstract No. 2111
Dong, S.; Stenoien, D.L.; Mancini, M.A.; Tweardy, D.J. 2002: PML-RARalpha Sequesters RXRalpha to Sites within the Nucleus Distinct from RARalpha and Reduces RXRalpha Intranuclear Mobility in Live Cells. Blood 100(11): Abstract No. 2073
Jing, Y.; Xia, L.J.; Hellinger, N.; Waxman, S. 2000: PML-RARalpha degradation is necessary for the synergistic differentiation induced by all-trans retinoic acid in combination with butyrates or HMBA. Proceedings of the American Association for Cancer Research Annual Meeting 41: 807
Kabuli, M.; Yin, J.A.L.u; Tobal, K. 2003: PML/RARA-targeting DNAzymes suppress proliferation and induce apoptosis in ATRA-sensitive and ATRA-resistant APL cells. British Journal of Haematology 121(Suppl 1): 73-74
Pintucci, S.; Sarra, A.; Caiazza, S. 1999: PMMA/Dacron biointegrated keratoprosthesis 19 Years of experience. IOVS Investigative Ophthalmology and Visual Science 40(4): S104
Cepinskas, G.; Savickiene, J.; Lush, C.W.; Kvietys, P.R. 2000: PMN transendothelial migration provides a negative feedback on endothelial cell nuclear NFkappaB and influences survival of endothelial cells in culture. FASEB Journal 14(4): A705
Lindsey, M.L.; Wedin, K.E.; Brown, M.D.; Jackson, P.; Rossen, R.D.; Michael, L.H.; Entman, M.L. 1999: PMNs are the early source of MMP 9 following myocardial I/R injury. FASEB Journal 13(4 Part 1): A206
Magnaghi, V.; Cavarretta, I.; Zucchi, I.; Bovolin, P.; D'urso, D.; Martini, L.; Melcangi, R.C. 1999: PMP22 and Po gene expression Influence of progesterone derivatives. Society for Neuroscience Abstracts 25(1-2): 484
Tsai, C.C.; Sun, J.C.; Emau, P.; Tian, B.; Jiang, Y.; Morton, W.R.; Bischofberger, N. 2002: PMPA gel as a topical microbicide for preventing rectal transmission of SHIV896P in macaques. Journal of Medical Primatology 31(4-5): 297-298
Smith, M.S.; Foresman, L.; Li, Z.; Wang, C.; Kumar, A.; Bischofberger, N.; Narayan, O. 1999: PMPA inhibition of SHIVKU2-infection in rhesus macaques. Journal of Medical Primatology 28(4-5): 282
Van Rompay, K.; Cherrington, J.M.; Marthas, M.L.; Lamy, P.; Dailey, P.J.; Canfield, D.R.; Tarara, R.P.; Bischofberger, N.; Pedersen, N.C. 1999: PMPA therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Journal of Medical Primatology 28(4-5): 282
Devore, L.; Kinsella, B. 2001: PMR catheter. Official Gazette of the United States Patent and Trademark Office Patents 1245(3)
Melby, M.K.; Smith, E.O. 1999: PMS A bioculture-bound syndrome. American Journal of Physical Anthropology (Suppl 28): 200
Mannella, L.C. 2001: PMS defense an aromatherapy compound for the relief of symptoms of premenstrual syndrome. Official Gazette of the United States Patent and Trademark Office Patents 1252(4)
O'brien, P.M.S. 2000: PMS/PMDD Who should treat?. Neuropsychopharmacology 23(S2): S97
Qin, X.; Zhou, H.; Liu, L.; Gerson, S.L. 1999: PMS2-deficient mice are hypersensitive to GI tumor induction byh azoxymethane and protected byh MGMT overexpression. Proceedings of the American Association for Cancer Research Annual Meeting 40: 57
Engelbregt, M.J.T.; Van Weissenbruch, M.M.; Popp Snijders, C.; Delemarre Van, D.W.al, H.A. 2000: PMSG induces multiple follicular development and superovulation in intra uterine growth retarded rats at the onset of puberty. Hormone Research 53(Suppl 2): 81
Siguroardóttir, O.G.; Gunnarsson, E.; Konraosson, K. 2010: PMWS in pigs in Iceland. Veterinary Record 166(7): 216
Karmous, H.; Laudier, B.; Lapierre, J.M.; Sanlaville, D.; Lyonnet, S.; Attie, T.; Vekemans, M.; De Blois, M.C.; Amiel, J.; Romana, S.P. 2002: PMX2B, a new candidate gene for Hirschsprung disease. American Journal of Human Genetics 71(4 Suppl): 273
Gantier, J.C.; Bain, O. 2004: PN Vuong - Physician, anatomopathologist and parasitologist. Parasite 11(2): 130
Pina Rodrigues, E.; Ahuja, D.; Mirza, A.; Benawra, R.; Angst, D.B. 2002: PN-related cholestasis in neonates What role do vitamin preparations play?. Pediatric Research 51(4 Part 2): 318A
Hodge, K.; Tandon, P.; Gonzalez, A.; Brenneman, D.; Cardin, S.; Von Borstel, R. 2003: PN2034 Comparison and combination with metformin in ob/ob mice. Diabetes 52(Suppl 1): A460
Brenneman, D.; Song, X.; Morrow, E.; Gonzalez, A.; Arudchandran, R.; Wolpe, S.; Von Borstel, R.; Cardin, S. 2003: PN2034 normalizes insulin responsiveness in rats on a high fat diet. Diabetes 52(Suppl 1): A458
Saif, M.W.; Hodge, K.; Poortman, C.; Von Borstel, R. 2003: PN401 rescue from the lethal toxicity of 5-FU in mice. Proceedings of the American Association for Cancer Research Annual Meeting 44: 744
Coull, J.; Fitzpatrick, R. 2001: PNA and DNA conjugates and methods for preparation thereof. Official Gazette of the United States Patent and Trademark Office Patents 1244(1)
Kuppusamy, P.; Li, H.; Ilangovan, G.; Ma, L.; Hsia, C.J.C. 2001: PNA as a tumor radiosensitizer Enhancement of vascular volume and oxygenation. Free Radical Biology and Medicine 31(10): S139
Lomholt, B.; Frederiksen, S.; Nielsen, P.E. 2000: PNA as specific probe for in situ hybridization to metaphase chromosomes. Kessler, Christoph Springer Lab Manuals Nonradioactive analysis of biomolecules Second Edition 478-483
Fiandaca, M.J.; Hyldig Nielsen, J.J.; Coull, J.M. 1999: PNA blocker probes enhance specificity in probe assays. Nielsen, P E, Egholm, M Peptide nucleic acids: Protocols and applications: 129-141
Veeneman, Jorden M.; Kingma, Hermi A.; Stellaard, Frans; De Jong, Paul E.; Reijngoud, Dirk Jan; Huisman, Roel M. 2001: PNA calculations do not reflect protein oxidation in hemodialysis patients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 458A
Cook, P.D.; Kiely, J.; Sprankle, K. 2001: PNA combinatorial libraries and improved methods of synthesis. Official Gazette of the United States Patent and Trademark Office Patents 1244(3)
Nie, E.X.ao Feng; Wu, Y.M.n 2000: PNA diagnostic methods. Official Gazette of the United States Patent and Trademark Office Patents 1234(2)
Demidov, V.V.; Frank Kamenetskii, M.D. 1999: PNA directed genome rare cutting. Nielsen, P E, Egholm, M Peptide nucleic acids: Protocols and applications 163-174
Batz, H.G.; Hansen, H.F.; Orum, H.; Koch, T.; Shuster, G.B.; Armitage, B.A. 2000: PNA monomers with electron donor or acceptor. Official Gazette of the United States Patent and Trademark Office Patents 1238(2)
Koch, T. 1999: PNA oligomer synthesis by Boc chemistry. Nielsen, P E, Egholm, M Peptide nucleic acids: Protocols and applications 21-37
Pellestor, F.; Andreo, B.; Ribot, N.; Lefort, G. 2003: PNA on human sperm, a new approach for in situ aneuploidy detection. Annales de Genetique 46(2-3): 187-188
Egholm, M.; Perry O'keefe, H. 2000: PNA pre-gel hybridization An alternative to southern blotting. Kessler, Christoph Springer Lab Manuals Nonradioactive analysis of biomolecules Second Edition 464-467
Hyldig Nielsen, J.J.; Godskesen, M.A. 2001: PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis. Official Gazette of the United States Patent and Trademark Office Patents 1242(1)
Hyldig Nielsen, J.J.; Coull, J.M. 2003: PNA probes, probe sets, methods and kits pertaining to the detection of microorganisms. Official Gazette of the United States Patent and Trademark Office Patents 1277(3)
Hyldig Nielsen, J.J.; O'keefe, H.P. 2001: PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya. Official Gazette of the United States Patent and Trademark Office Patents 1249(4)
Breipohl, G.; Uhlmann, E.; Knolle, J. 2000: PNA synthesis using a base-labile amino protecting group. Official Gazette of the United States Patent and Trademark Office Patents 1238(3)
Breipohl, G.; Uhlmann, E. 2000: PNA synthesis using an amino protecting group which is labile to weak acids. Official Gazette of the United States Patent and Trademark Office Patents 1233(1)
Gildea, B.D.; Coull, J.M. 2001: PNA synthons. Official Gazette of the United States Patent and Trademark Office Patents 1248(4)
Romanelli, A.; Saviano, M.; Pedone, C.; Borgatti, M.; Bianchi, N.; Mischiati, C.; Gambari, R. 2002: PNA-DNA chimeras as decoy molecules against the transcription factor Sp1. Journal of Peptide Science 8(Suppl): S59
Egholm, M.; Chen, C. 2002: PNA-DNA chimeric probe arrays and methods of use. Official Gazette of the United States Patent and Trademark Office Patents 1263(4)
Cook, Phillip Dan 2001: PNA-DNA-PNA chimeric macromolecules. Official Gazette of the United States Patent and Trademark Office Patents 1249(3)
Matysiak, S.; Wurtz, S.; Hauser, N.C.; Gausepohl, H.; Hoheisel, J.D. 1999: PNA-arrays for nucleic acid detection. Nielsen, P E, Egholm, M Peptide nucleic acids: Protocols and applications 119-128
Frank Kamenetskii, M.D.; Kuhn, H.; Demidov, V.V. 2000: PNA-based DNA nanostructures. Journal of Biomolecular Structure and Dynamics 17(6): 1168-1169
Uhlmann, E.; Greiner, B.; Breipohl, G. 1999: PNA/DNA chimeras. Nielsen, P E, Egholm, M Peptide nucleic acids: Protocols and applications 51-70
Suarez, C.; Bertolone, S.; Raj, A. 2002: PNET of bone with germline p53 mutation as a second malignancy in ALL of childhood Case report and literature review. Pediatric Research 51(4 Part 2): 257A
Feland, J.B.; Myrer, J.W.; Merrill, R.M. 2001: PNF vs static stretch Acute responses in hamstring flexibility of senior athletes. Medicine and Science in Sports and Exercise 33(5 Suppl): S10
Takahashi, Y.; Mccoy, J.P.; Carvallo, C.; Rivera, C.; Igarashi, T.; Srinivasan, R.; Young, N.; Childs, R. 2002: PNH Cells Are Not Resistant to Allogeneic Immune Attack and Can Be Eradicated Following Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood 100(11): Abstract No. 21
Olbert, P.; Von Knobloch, R.; Varga, Z.; Heidenreich, A.; Hofmann, R. 2003: PNL with the Swiss Litho Clast Master Evaluation of complications and outcome after combined pneumatic and ultrasonic lithotripsy in 90 patients. Journal of Urology 169(4 Suppl): 474
Singh, R.H.; Crawford, K.; Graham, P.; Ellsworth, K.; Strumlauf, E.; Elsas, L.J.II 2000: PNO-metab Listserv Instantaneous communication world wide for registered dieticians working with patients with inborn errors of metabolism. Journal of Inherited Metabolic Disease 23(Suppl 1): 285
Catacuzzeno, L.; Nonner, W.; Eisenberg, B. 1999: PNP2 links crystallographic structure and conduction in K channels. Biophysical Journal 76(1 Part 2): A79
Rossin, R.; Schibli, R.; Visentin, R.; Ortner, K.; Alberto, R.; Schubiger, A.; Mazzi, U. 2001: PNS as tridentate ligand system for the synthesis of Tc and Re tricarbonyl complexes. Journal of Labelled Compounds and Radiopharmaceuticals 44(Suppl 1): S510-S512
Moreno, T.A.; Bronner Fraser, M. 2001: PNS precursor cells. Rao, Mahendra S Contemporary Neuroscience Stem cells and CNS development 153-176
Heyrman, R.M.; Columbo, M.; Smith, K.S.; Le, V.H.; Creticos, P.S. 2000: PNU-142731A An exploratory multiple oral dose nasal allergen challenge study in atopic subjects with allergic rhinitis. Journal of Allergy and Clinical Immunology 105(1 part 2): S203
Maj, R.; Calabresi, M.; Caccia, C.; Salvati, P.; Fariello, R.G. 1999: PNU-151774E, a combined MAO-B and glutamate release inhibitor, is effective in animal models of Parkinsons disease. Society for Neuroscience Abstracts 25(1-2): 1599
Salvati, P.; Maj, R.; Mc Arthur, R.A.; Cervini, M.A.; Kozak, W.; Benatti, L.; Fariello, R.G. 1999: PNU-151774E, a novel NA+ channel blocker, shows analgesic effects in some animal models. Society for Neuroscience Abstracts 25(1-2): 1947
Della Torre, P.; Podestà, A.; Imondi, A.R.; Moneta, D.; Sammartini, U.; Arrigoni, C.; Terron, A.; Brughera, M. 2001: PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential. Cancer ChemoTherapy and Pharmacology 47(4): 355-360
Geroni, C.; Pennella, G.; Howard, M.; Broggini, M.; Marchini, S.; Cozzi, P.; Fowst, C. 2000: PNU-166196 A novel antitumor agent whose cytotoxicity is enhanced in tumor cells with high levels of glutathione. Tumori 86(4 Suppl 1): 41-42
Geroni, C.; Cozzi, P.; Broggini, M.; Marchini, S.; Galliera, E.; Beria, I.; D'incalci, M. 2001: PNU-166196, a novel DNA minor groove binder with enhanced activity in tumors expressing high gluthathione and/or Glutathione-S-transferase levels. International Journal of Molecular Medicine 8(Suppl 1): S10
Geroni, C.M.; Broggini, M.; Colombo, T.; D'incalci, M.; Galliera, E.; Marchini, S. 2001: PNU-166196, a novel antitumor agent with enhanced activity in tumors expressing high glutathione and/or glutathione-S-transferase levels. Proceedings of the American Association for Cancer Research Annual Meeting 42: 326
Vonderfecht, S.; Schemmer, J.; Stone, M.; Schuette, M.; Norris, L.; Waldon, D.; Ware, J. 2001: PNU-177864 Multidose drug distribution analysis and prediction of toxicity in a repeated-dose toxicity study. Toxicologic Pathology 29(6): 713
Golub, A.S.; Pittman, R.N. 2002: PO2 determination using laser excitation in phosphorescence quenching microscopy. FASEB Journal 16(4): A520-A521
Smith, L.M.; Barbee, R.W.; Ward, K.R.; Pittman, R.N. 2002: PO2 measurements in the spinotrapezius muscle of spontaneously hypertensive rats following muscle contraction. FASEB Journal 16(4): A519
Mostafa, S.S.; Papoutsakis, E.T.; Miller, W.M. 2001: PO2 modulates megakaryocyte expression of cytokine receptors, transcription factors, and lineage-specific markers. Abstracts of Papers American Chemical Society 221(1-2): BIOT 257
Uchida, T.; Yokoyama, K.; Nakazawa, K.; Makita, K. 1999: PO2 of the perfluorocarbon liquid during partial liquid ventilation. Anesthesiology 91(3A): A1342
Shoemaker, J.L.Jr; Westen, E.A.; Marciano Lee, P.N.; Pagel, M.D.; Daleke, D.L.; Prange, H.D. 1999: PO2-dependent binding of chloride to hemoglobin A mechanism underlying the chloride shift. FASEB Journal 13(4 Part 1): A130
Baines, D.L.; Ramminger, S.J.; Collett, A.; Best, O.G.; Olver, R.E.; Wilson, S.M. 2000: PO2-evoked increases in epithelial Na+ channel alpha-subunit gene transcription and Na+ transport in fetal rat distal lung epithelial cells. Journal of Physiology (Cambridge) 527P: 24P
Marcinek, D.J.; Ciesielski, W.A.; Conley, K.E.; Schenkmen, K.A. 2002: PO2crit is independent of tissue oxygen consumption in mouse skeletal muscle. FASEB Journal 16(5): A769
Ehrmeyer, S.S. 2001: POCT Perspective and experience from the USA. Clinical Chemistry and Laboratory Medicine 39(special Suppl): S71
Campos, J. 2001: POCT for infectious diseases Making up for lost time. Clinical Chemistry 47(S6): S21
Morimura, N.; Tezuka, Y.; Watanabe, N.; Yasuda, M.; Miyatani, S.; Hozumi, N.; Tezuka, K. 2001: POEM A novel pre-osteoblastic ligand molecule for alpha8beta1 integrin. Journal of Bone and Mineral Research 16(Suppl 1): S189
Helmersen, D.S.; Ford, G.T.; Viner, S.M.; Auger, W.R. 2000: POEMS syndrome: a clue to understanding primary pulmonary hypertension? a review of current insights into the pathogenesis of primary pulmonary hypertension. Canadian Journal of Cardiology 16(8): 975-981
Ahmad, M.E.; Dada, R.; Kucheria, K. 2003: POF in a mentally retarded girl with epilepsy and duplication of p arm of chromosome 22. American Journal of Human Genetics 73(5): 291
Ben Mrad, F.; Abdelmoula, N.B.; Amouri, A.; Saad, A.; Abid, M.; Rebai, T. 2003: POF-related chromosomal abnormalities. Annales de Genetique 46(2-3): 229
Bione, S.; Rizzolio, F.; Battaglia, R.; Murray, A.; Marozzi, A.; Vegetti, W.; Modena, P.; Manzini, M.C.; Ricotti, R.; Dalpra, L.; Crosignani, P.G.; Jacobs, P.; Conway, G.S.; Toniolo, D. 2000: POF2 gene may be responsible for the ovarian phenotype of Turner Syndrome. American Journal of Human Genetics 67(4 Suppl 2): 352
Maeda, T.; Hobbs, R.; Guernah, I.; Khandker, L.; Cordon Cardo, C.; Pandolfi, P.P.olo 2003: POKEMON plays a key role in oncogenic transformation and repression of p19ARF. Blood 102(11): 136a
Kolsut, P.; Religa, G.; Siondalski, P.; Brzozowski, M.; Mizerski, J.; Lango, R.; Stefaniak, M.; Narkiewicz, M.; Religa, Z.; Kustosz, R. 2002: POLVAD system as a bridge to recovery in fulminant myocarditis. International Journal of Artificial Organs 25(7): 682
Theunissen, P.M.V.M.; Kooijman, J.; Van Der Meer, S.B. 2000: POMC deficiency, a striking phenotype Adrenal insufficiency, infantile obesity and red hair A case report. Hormone Research 53(Suppl 2): 68
Fukabori, R.; Yamamoto, T. 2000: POMC gene expression is induced by the taste stimulation. Neuroscience Research Suppl (24): S114
Tsatmali, M.; Yukitake, J.; Thody, A.J. 2000: POMC peptides and the regulation of the human melanocortin 1 receptor. British Journal of Dermatology 142(3): 605
Koban, M.; Hoffman, G.E.; Le, W.W.i 2004: POMC-Neurons in Arcuate Nucleus are Down-Regulated During Chronic Sleep Deprivation Stress in Rats. FASEB Journal 18(4-5): Abstract 455
Vervoort, V.S.; Holden, K.R.; Ukadike, K.C.; Saul, R.A.; Srivastava, A.K. 2003: POMGnT1 gene mutations in a family with mental retardation, glaucoma, and congenital muscular dystrophy. Annals of Neurology 54(Suppl 7): S154-S155
Tanzer, R.J.; Longbottom, D.; Hatch, T.P. 1999: POMPs of Chlamydia psittaci and Chlamydia trachomatis are late-stage specific. Abstracts of the General Meeting of the American Society for Microbiology 99: 226
Sozmen, B.; Sozmen, E.Y.; Tanrisev, M.; Aslan, L. 2000: PON phenotypes, as prognostic markers in management of intoxication with organo phosphorus pesticides. Drug Metabolism Reviews 32(Suppl 1): 105
Choi, L.; Furlong, C.E.; Jarvik, G.P. 2000: PON1192 genotype and its relationship to serum lipids and lipoproteins in subjects with carotid artery disease. Journal of Investigative Medicine 48(1): 88A
Pignatti, P.F.; Girelli, D.; Martinelli, N.; Olivieri, O.; Pizzolo, F.; Friso, S.; Tenuti, I.; Corrocher, R.; Grow, M.; Cheng, S.; Trabetti, E. 2003: PON2 Ser311Cys genotype, and its interaction with smoking, increase the risk of myocardial infarction in patients with coronary atherosclerosis. American Journal of Human Genetics 73(5): 516
L.D., B.N.; Draganov, D.I.; Stetson, P.L.; Watson, C.E. 2003: PON3 and uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1271(1)
Visser, K.; Hassink, E.; Bonsel, G.; Kalkman, C. 1999: PONV following anesthesia with isoflurane/N2O vs TIVA with propofol A randomized blinded practice-based trial in 554 outpatients. Anesthesiology 91(3A): A8
Mccairn, M.C.; Sutherland, A.J. 2002: POP art Designer polymers for use in combinatorial chemistry. Abstracts of Papers American Chemical Society 224(1-2): ORGN 434
Darnerud, P.O.; Lignell, S.; Glynn, A.; Aune, M.; Törnkvist, A.; Stridsberg, M. 2010: POP levels in breast milk and maternal serum and thyroid hormone levels in mother-child pairs from Uppsala, Sweden. Environment International 36(2): 180-187
Palanivelu, R.; Wilhelmi, L.K.; Preuss, D. 2001: POP2, a gene required for guidance of Arabidopsis pollen tubes, is similar to class III omega aminotransferases. Developmental Biology 235(1): 211
Narula, J. 2000: 'POPE': Predicting outcome by plaque evaluation. Nuclear Medicine Communications 21(7): 601-608
Payne, J.; Anderson, R. 2002: POPs and mercury in aquatic foodwebs of subsistence lakes in Labrador. Canadian Technical Report of Fisheries and Aquatic Sciences 2403: 169
Pelley, J. 2004: POPs levels linked to climate fluctuations. Environmental Science and Technology 38(9): 156a
Burke, M. 2004: POPs treaty takes flight. Environmental Science and Technology 38(9): 157A
Finchman, J.E. 1999: PORT and PORT-II abstracts Program update US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and Center for Medical Effectiveness Research. Journal of Pharmacoepidemiology 7(2): 3-40
Lebedev, N.; Timko, M.P. 1999: PORb catalyzed pchlorophyllide photoreduction in vitro Insight into mechanism of chlorophyll formation in light-adapted plants. Plant Biology (Rockville) : 167
Welch, D.; Boehlert, G. 2002: POST The Pacific Ocean Salmon Tracking Project. AAAS Annual Meeting and Science Innovation Exposition 168: A33-A34, 14-19 February
Andersen, B.; Rosenfeld, M.G. 2001: POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocrine Reviews 22(1): 2-35
Wierman, M.E.; Xu, M.; Zeng, C.; Allen, M.P. 1999: POU domain proteins in GT1-7 neuronal cells Activation of the gonadotropin releasing hormone promoter by OCT3/4. Journal of Investigative Medicine 47(2): 22A
Lee, D.K.; Kwon, H.S.; Edenberg, H.J.; Hur, M.W. 2002: POZ-domain proteins and histone deacetylase repress transcription by interacting with zinc-finger DNA binding domain of Sp1 transcription factor. FASEB Journal 16(5): A1190
Anonymous 2003: PP 3/3 Environmental risk assessment scheme for plant protection products Chapter 4 Soil. Bulletin Oepp 33(2): 151-162
Anonymous 2003: PP 3/4 Environmental risk assessment for plant protection products Chapter 5 Groundwater. Bulletin Oepp 33(2): 163-168
Anonymous 2003: PP 3/7 Environmental risk assessment scheme for plant protection products Chapter 8 Soil organisms and functions. Bulletin Oepp 33(2): 209
Parameswara, V.; Thangthaeng, N.; Bhatt, H.; Easom, R. 2003: PP-2A is associated with synapsin I in INS-1 cells and regulates insulin secretion. Diabetes 52(Suppl 1): A383
Bennett, D.H.; Szoor, B.; Alphey, L.S. 2000: PP1 and developmental signalling. Biochemical Society Transactions 28(5): A425
Huang, H.; Farley, J. 1999: PP1 inhibitors mimic and occlude learning-produced changes in Hermissenda Type B photoreceptor excitability. Society for Neuroscience Abstracts 25(1-2): 1612
Dubell, W.H.; Rogers, T.B. 2004: PP1 regulates the steady-state amplitude of the murine ventricular L-type Ca current. Biophysical Journal 86(1): 228a
Terrak, M.; Kerff, F.; Langsetmo, K.; Gong, B.J.; Tao, T.; Dominguez, R. 2004: PP1 targeting and regulation as revealed by the structure of a PP1delta-MYPT1 complex. Biophysical Journal 86(1): 172a
Warmuth, M.; Schuster, C.; Forster, K.; Simon, N.; Mathes, R.; Hallek, M. 2000: PP1, a Src-specific tyrosine kinase inhibitor, selectively inhibits survival of Bcr-Abl expressing myeloid cells. Onkologie 23(Sonderheft 7): 86
Tykocinski, M.L.; Riely, G.J. 2004: PP14 fusion proteins and methods for making and using the same. Official Gazette of the United States Patent and Trademark Office Patents 1286(4)
Guo, C.Y.; Larner, J.M. 2002: PP1c links ATM to the downstream damage-response effector proteins HDAC1 and Rb. International Journal of Radiation Oncology Biology Physics 54(2 Suppl): 52-53
Seeling, J.M.; Li, X.; Yost, H.J.; Virshup, D.M. 2001: PP2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus. Developmental Biology 235(1): 254
Ugi, S.; Maegawa, H.; Egawa, K.; Kashiwagi, A.; Imamura, T.; Olefsky, J. 2003: PP2A as a negative regulator of the insulin signaling through inhibition of Akt and PKC lambda in 3T3-L1 adipocytes. Diabetes 52(Suppl 1): A311
Kawada, M.; Yoshimoto, Y.; Kumagai, H.; Someno, T.; Momose, I.; Kawamura, N.; Isshiki, K.; Ikeda, D. 2004: PP2A inhibitors, harzianic acid and related compounds produced by fungus strain F-1531. Journal of Antibiotics 57(3): 235-237
Ugi, S.; Imamura, T.; Olefsky, J.M. 2001: PP2A negatively regulates the Ras-MAP kinase pathway via binding to Shc and inhibiting Shc tyrosine phosphorylation. Diabetes 50(Suppl 2): A290
Yamaguchi, Y.; Katoh, H.; Negishi, M. 2003: PP5 is a novel effector of G12 family. Neuroscience Research Suppl (26): S22
Moores, C.; Mcqueen, D.S.; Bond, S.M. 2002: PPADS, respiratory chemoreflexes and carotid sinus nerve discharge in anaesthetised rats. British Journal of Pharmacology 135(Proceedings Suppl): 34P
Hodis, H.N.; Buchanan, T.A.; Li, Y.; Torres, M.; Mack, W.J. 2003: PPAR activation and progression of subclinical atherosclerosis in insulin requiring type 2 diabetes mellitus. Circulation 108(17): IV741
Mcnamara, P.; Lawson, J.A.; Rokach, J.; Fitzgerald, G.A. 1999: PPAR activation by isoprostanes A signaling mechanism for oxidant injury. Circulation 100(18): I480-I481
Goetze, S.; Eilers, F.; Bungenstock, A.; Kintscher, U.; Spencer, C.; Graf, K.; Fleck, E.; Grafe, M. 2001: PPAR activators inhibit endothelial cell migration and VCAM-1 expression. European Heart Journal 22(Abstract Suppl): 644
Hayward, C.M.; Perry, D.A. 2004: PPAR agonists. Official Gazette of the United States Patent and Trademark Office Patents 1280(1)
Buchan, K.W.; Hassall, D.G. 2000: PPAR agonists as direct modulators of the vessel wall in cardiovascular disease. Medicinal Research Reviews 20(5): 350-366
Wilson, T.M.; Collins, J.L.; Henke, B.R.; Brown, P.J.; Lambert, M.H.; Xu, H.E.; Oplinger, J.A. 2000: PPAR agonists for metabolic diseases. Abstracts of Papers American Chemical Society 220(Part 1): MEDI 197
Francis, G.A.; Annicotte, J-Sébastien.; Auwerx, J. 2003: PPAR agonists in the treatment of atherosclerosis. Current Opinion in Pharmacology 3(2): 186-191
Chatterjee, P.K.; Sivarajah, A.; Todorovic, Z.; Thiemermann, C. 2002: PPAR agonists reduce renal dysfunction caused by ischemia/reperfusion of the kidney of the rat Comparison of PPARalpha and PPARgamma agonists. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 136A
Chinetti, G.; Lestavel, S.; Fruchart, J.C.; Clavey, V.; Staels, B. 2001: PPAR alpha controls cholesterol homeostasis in human monocyte-derived macrophages. Circulation 104(17): 2; 233-II 234
Anderson, S.P.; Swanson, C.; Everitt, J.; Corton, J.C. 2003: PPAR alpha plays a major role in determining the gene expression profile altered by caloric restriction. Toxicological Sciences 72(S-1): 340
Corton, J.C.; Anderson, S.P.; Stauber, A.J.; Laughter, A.; Swanson, C.; Xiao, S.; Everitt, J.; Voss, K. 2003: PPAR alpha-dependent alterations in chemical-induced stress and longevity correlates with increased expression of heat shock proteins. Toxicological Sciences 72(S-1): 340
Letavernier, E.; Perez, J.; Joye, E.; Peltier, J.; Bellocq, A.; Fouqueray, B.; Haymann, J.P.; Desvergne, B.; Wahli, W.; Baud, L. 2004: PPAR beta has an important role in promoting preservation of kidney function during acute ischemic renal failure. Mediators of Inflammation 13(1): 61
Sakuma, S.; Endo, T.; Tendo, A.; Takahashi, T.; Yoshida, S.; Kobayashi, K.; Mochizuki, N.; Yamakawa, T.; Kanda, T.; Masui, S. 2004: PPAR delta activators. Official Gazette of the United States Patent and Trademark Office Patents 1286(1)
Fischer, S.M.; Thuillier, P.; Muga, S.J.; Belury, M. 1999: PPAR expression and activity in murine skin tumors. Prostaglandins and Other Lipid Mediators 59(1-6): 89
Bagi, Z.; Koller, A.; Kaley, G. 2004: PPAR gamma Activation Improves Wall Shear Stress Dependent Regulation of Coronary Arteriolar Diameter in Type 2 Diabetes Mellitus. FASEB Journal 18(4-5): Abstract 430
Dobrian, A.D.; Ambrozewicz, M.; Chung Debose, S. 2004: PPAR gamma Regulates Expression of Sodium Transporters in Renal Proximal Tubule Epithelial Cells Independent of Oxidative Stress. FASEB Journal 18(4-5): Abstract 458
Wagner, J.A.; Flynn, M.E.; Knops, A.; Hartford, A.H.; Dallob, A.L.; Tanaka, W.K.; Desmet, M.; Van Dyck, K.; Stevens, C.; Scherer, P.E.; Gottesdiener, K.M. 2003: PPAR gamma activation rapidly increases ACRP30 in non-diabetic subjects. Clinical Pharmacology and Therapeutics 73(2): P75
Roth, A.D.; Leisewitz, A.V.; Inestrosa, N.C.; Bronfman, M. 2002: PPAR gamma activators induce differentiation of B12 oligodendrocyte-like cells and rat spinal cord oligodendrocytes. Journal of Neurochemistry 81(Suppl 1): 48
Corti, R.; Osende, J.I.; Wright, S.D.; Fallon, J.T.; Jneid, H.; Dickstein, E.; Fuster, V.; Badimon, J.J. 2002: PPAR gamma agonist L-805645 induces regression of atherosclerotic lesions, decreases inflammation, and increases smooth-muscle cells. European Heart Journal 23(Abstract Suppl): 19
Ota, S.; Kato, A.; Matsuzaki, F. 1999: PPAR gamma agonist stimulates vascular endothelial growth factor production by human macrophages. Gastroenterology 116(4 Part 2): A482
Jiang, G.; Dallas Yang, Q.; Biswas, S.; Li, Z.; Zhang, B. 2003: PPAR gamma agonists reduce inhibitory serine 307 and 612 phosphorylation of IRS1 both in vitro and in vivo. Diabetes 52(Suppl 1): A307
Nofziger, C.; Chen, L.; Smith, C.D.; Brown, K.K.; Blazer Yost, B.L. 2004: PPAR gamma agonists, Pioglitazone and GW7845, do not affect insulin-stimulated Na+ transport in the mouse M1 cortical collecting duct cell line. FASEB Journal 18(4-5): Abstract 681
Nissim, I.; Routh, R.; Lazarow, A.; Welbourne, T. 2002: PPAR gamma antagonist BADGE blocks troglitazone induced ammoniagenesis in proximal tubule-like LLC-PK1-F+ cells. FASEB Journal 16(5): A1169-A1170
Bright, J.J.; Raikwar, H.P.; Muthian, G. 2004: PPAR gamma antagonist, bisphenol A diglycidyl ether, exacerbates neural antigen-induced Th1 response and experimental allergic encephalomyelitis. FASEB Journal 18(4-5): Abstract 780
Goetze, S.; Kintscher, U.; Kaneshiro, K.; Hsueh, W.A.; Law, R.E.; Fleck, E. 2000: PPAR gamma inhibits the nuclear but not the cytosolic branch of MAPK-regulated VSMC migration. European Heart Journal 21(Abstract Suppl): 482
Mutamba, B.; Morrison, R.F. 2004: PPAR gamma ligand-dependent repression of adipocyte gene expression. FASEB Journal 18(4-5): Abstract 585
Tenner, T.E.; Hendley, R.T.; Clowe, J.D.; Davis, R.L.; Dertien, J.S.; Mcmahon, K.K. 2003: PPAR gamma ligands inhibit proliferation and induce lipid accumulation in rabbit vascular smooth muscle cell cultures. FASEB Journal 17(4-5): Abstract 658
Nissim, I.; Routh, R.E.; Lazarow, A.; Welbourne, T.C. 2001: PPAR gamma regulates glutamine metabolism in proximal tubule-like LLC-PK1-F+ cells. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 52A
Corti, R.; Osende, J.I.; Fuster, V.; Wright, S.D.; Fayad, Z.A.; Dickstein, E.; Fallon, J.T.; Badimon, J.J. 2002: PPAR gamma-agonist induces regression of atherosclerotic plaques In vivo study by high resolution magnetic resonance imaging. Journal of the American College of Cardiology 39(5 Suppl A): 248A-249A
Spearing, P.K.; Oplinger, J.A.; Henke, B.R.; Collins, J.L.; Lessnitzer, L.; Parks, D.J.; Plunket, K.D. 2001: PPAR gamma/alpha dual agonists SAR studies of vinylogous amide tyrosine analogs. Abstracts of Papers American Chemical Society 221(1-2): MEDI 239
Etgen, G.J.; Mantlo, N. 2003: PPAR ligands for metabolic disorders. Current Topics in Medicinal Chemistry 3(14): 1649-1661
Berger, J. 2002: PPAR ligands for the treatment of metabolic syndrome New challenges and opportunities for molecular pharmacology. International Journal of Obesity 26(Suppl 1): S160
Kelly, D.P.; Lehman, J.J.; Barger, P.M.; Huss, J.M.; Weinheimer, C.J.; Kovacs, A.; Courtois, M.R.; Leone, T.C. 2001: PPAR signaling in the control of cardiac energy metabolism Lessons from genetically altered mice. Journal of Molecular and Cellular Cardiology 33(6): A158
Smith, T.L.; Callahan, M.F. 2004: PPAR- gamma agonist effects on cardiac output and stroke volume and femoral blood flow in mice. FASEB Journal 18(4-5): Abstract 436
Zhang, X.; Young, H.A. 2004: PPAR- gamma represses interferon- gamma gene expression by sequestration of CBP/p300. FASEB Journal 18(4-5): Abstract 772
Toyama, T.; Marutama, R.; Yamauchi, A.; Harano, Y.; Nakamura, H.; Minami, M.; Itoh, Y.; Okanoue, T. 2003: PPAR-A activators, Wy-14,643 and fenofibrates, inhibit hepatic fibrosis in experimental rat model via antioxidant effect. Hepatology 38(4 Suppl 1): 337A
Feinstein, D.L.; Brosnan, C.F.; Whitacre, C.C.; Landreth, G.E.; Gavrilyuk, V.; Heneka, M.T. 2002: PPAR-agonists prevent experimental autoimmune encephalomyelitis. Journal of Neurochemistry 81(Suppl 1): 36
Shankar, K.; Vaidya, V.S.; Manautou, J.E.; Corton, J.C.; Bucci, T.J.; Liu, J.; Waalkes, M.P.; Mehendale, H.M. 2003: PPAR-alpha activation is essential for diabetes-induced resistance against acetaminophen hepatotoxicity. Toxicological Sciences 72(S-1): 195
Koh, E.H.; Park, H.S.; Ryu, J.W.; Kim, M.S.; Park, J.Y.; Lee, K.U. 2003: PPAR-alpha activation prevents diabetes mellitus in OLETF rats Comparison with PPAR-gamma. Diabetes 52(Suppl 1): A124
Trifilieff, A.; Bench, A.; Hanley, M.; Bayley, D.; Campbell, E.; Whittaker, P. 2003: PPAR-alpha and -gamma but not -delta agonists inhibit lung inflammation in a murine model of asthma. Inflammation Research 52(Suppl 2): S 86
Mcclure, T.D.; Young, M.E.; Taegtmeyer, H.; Ning, X.H.; Portman, M.A. 2002: PPAR-alpha and PGC-1 respond to alterations in thyroid hormone state in heart during maturation. Circulation 106(19): II99
Orthez, C.; Becker, J.; Auwerx, J.; Frossard, N.; Pons, F. 2004: PPAR-alpha decreases airway inflammation in a model of asthma. Mediators of Inflammation 13(1): 64
Jones, D.; Ding, X.; Daynes, R.A. 2000: PPAR-alpha expression in lymphocytes. FASEB Journal 14(6): A1172
Shankar, K.; Vaidya, V.S.; Manautou, J.E.; Bucci, T.J.; Corton, J.C.; Mehendale, H.M. 2002: PPAR-alpha mediates diabetes-induced resistance against acetaminophen hepatotoxicity Understanding mechanisms via microarray analyses. International Journal of Toxicology 21(6): 526
Brooks, D.A. 2001: PPAR-alpha, gamma co-agonists for the treatment of Type 2 diabetes and cardiovascular risk factors. Abstracts of Papers American Chemical Society 221(1-2): MEDI 175
Hellemans, K.; Rombouts, K.; Michalik, L.; Wahli, W.; Geerts, A. 2002: PPAR-beta and retinol metabolism related gene-expression in HSC. Journal of Hepatology 36(Suppl 1): 71
Schmuth, M.; Lau, P.; Chang, S.; Willson, T.; Elias, P.; Feingold, K. 2001: PPAR-delta ligands stimulate epidermal differentiation. Journal of Investigative Dermatology 117(2): 409
Sasaki, M.; Jordan, P.; Manas, K.; Welbourne, T.; Alexander, J.S.even 2002: PPAR-gamma activators prevent endothelial MAdCAM-1 induction mediated by TNF-alpha. FASEB Journal 16(4): A435
Rambasek, T.E.; Follettie, M.T.; Wang, I.W.; Wei, S.; Cai, J.; Bonfield, T.L.; Malur, A.; Barna, B.P.; Isabella, T.; Goldman, S.L.; Kavuru, M.S.; Kobayashi, M.; Thomassen, M. 2004: PPAR-gamma activity is deficient in alveolar macrophages of allergic asthmatics. Journal of Allergy and Clinical Immunology 113(2 Suppl): S191
Ji, J.D.; Choi, S.J.; Cheon, H.J.; Lee, Y.H.; Chae, I.J.; Yoo, D.H.; Sohn, J.; Song, G.G. 1999: PPAR-gamma agonist inhibits expression of TNF-alpha and IL-1 beta mRNA in cultured synoviocytes. Arthritis and Rheumatism 42(9 Suppl): S191
Murphy, G.J.; Holder, J.C. 2000: PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends in Pharmacological Sciences 21(12): 469-474
Kolb, H.C.; Mcgeehan, G.; Shi, Z.C.; Kolla, L.R.; Cavallaro, C. 2004: PPAR-gamma agonists as agents for the treatment of type II diabetes. Official Gazette of the United States Patent and Trademark Office Patents 1280(5)
Feinstein, D.L.; Gavrilyuk, V.; Weinberg, G.; Almeida, A.; Bolanos, J.P.; Galea, E.; Dello Russo, C. 2003: PPAR-gamma agonists increase glucose metabolism in astrocytes. Journal of Neurochemistry 85(Suppl 1): 81
Weber, S.M.; Corbett, J.A. 2001: PPAR-gamma agonists inhibit cytokine signaling in beta-cells. Diabetes 50(Suppl 2): A51
Zafiriou, S.; Pollock, C.A.; Poronnik, P. 2002: PPAR-gamma agonists modulate matrix formation and albumin uptake in opossum kidney cells. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 166A
Feinstein, D.L.; Sharp, A.; Brosnan, P.; Murphy, C.F.; Heneka, M.T. 2001: PPAR-gamma agonists prevent MOG-induced EAE. Journal of Neurochemistry 78(Suppl 1): 45
Chatterjee, P.K.; Sivarajah, A.; Todorovic, Z.; Mota Filipe, H.; Brown, P.A.J.; Stewart, K.N.; Thiemermann, C. 2003: PPAR-gamma agonists reduce renal dysfunction and injury caused by ischaemia/reperfusion of the rat kidney. British Journal of Pharmacology 138(Proceedings Suppl): 38P
Okano, H.; Shiraki, K.; Inoue, H.; Deguchi, M.; Sugimoto, K.; Sakai, T.; Ohmori, S.; Murata, K.; Nakano, T. 2002: PPAR-gamma augments death receptor signaling in hepatocellular carcinoma. Journal of Hepatology 36(Suppl 1): 82
Xiong, Z.; Li, J.; Wang, H. 2001: PPAR-gamma expression in actively proliferative glomerulonephritis. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 667A
Takagi, T.; Naito, Y.; Ichikawa, H.; Tomatsuri, N.; Imamoto, E.; Uchiyama, K.; Higashihara, H.; Handa, O.; Yoshida, N.; Yoshikawa, T. 2002: PPAR-gamma is a therapeutic target of in the management of gastric ischemic disease. Gastroenterology 122(4 Suppl 1): A-514
Wang, X.P.; Xu, X.F. 2002: PPAR-gamma is aberrantly expressed in pancreatic carcinoma tissue and cell line. Gastroenterology 122(4 Suppl 1): A-491
Bell, D.; Rotondo, F.; Kovacs, K.; Anderson, J.; Vidal, S.; Rowsell, C. 2004: PPAR-gamma is colocalized with Cox-2 in the oncocytes of the human parathyroid A histologic and immunohistochemical study. FASEB Journal 18(4-5): Abstract 787
Waechtershaeuser, A.; Loitsch, S.M.; Caspary, W.F.; Stein, J. 2000: PPAR-gamma is selectively upregulated during butyrate-induced differentiation of human colon carcinoma cells. Clinical Nutrition 19(Suppl 1): 26
Ihara, H.; Urano, T.; Loskutoff, D.J.; Takada, A. 2000: PPAR-gamma ligand and insulin induce type-1 plasminogen activator inhibitor gene transcription during adipocyte differentiation. Fibrinolysis and Proteolysis 14(Suppl 1): 21
Gacad, M.A.; Chun, R.F.; Adams, J.J. 1999: PPAR-gamma ligands as regulators of heat shock protein-70 -related intracellular vitamin D binding protein expression in the New World primate. Journal of Bone and Mineral Research 14(Suppl 1): S305
Dugo, L.; Pisano, B.; Wayman, N.; Ianaro, A.; Mazzon, E.; Caputi, A.P.; Thiemermann, C.; Cuzzocrea, S. 2003: PPAR-gamma ligands attenuate the development of intestinal ischemia/reperfusion. British Journal of Pharmacology 138(Proceedings Suppl): 40P
Jozkowicz, A.; Dulak, J.; Piatkowska, E.; Placha, W.; Dembinska Kiec, A. 2000: PPAR-gamma ligands increase the generation of VEGF. Journal of Submicroscopic Cytology and Pathology 32(3): 452
Takashima, T.; Fujiwara, Y.; Higuchi, K.; Arakawa, T.; Yano, Y.; Hasuma, T.; Otani, S. 2001: PPAR-gamma ligands induce G1 cell cycle arrest and reduce ornithine decarboxylase activity of human Barretts adenocarcinoma cells. Gastroenterology 120(5 Suppl 1): A 415
Weber, S.; Corbett, J. 2003: PPAR-gamma ligands induce the unfolded protein response in beta-cells. Diabetes 52(Suppl 1): A385
Han, C.; Demetris, A.J.; Michalopoulos, G.K.; Wu, T. 2002: PPAR-gamma ligands inhibit human cholangiocarcinoma cell growth through activation of P53 and GADD45/p21 pathway. Hepatology 36(4 Part 2): 309A
Yuan, Z.-y.; Liu, Y.; Liu, Y.; Zhang, J.-j.; Kishimoto, C.; Wang, Y.-n.; Ma, A.-q.; Liu, Z.-q. 2004: PPAR-gamma ligands inhibit the expression of inflammatory cytokines and attenuate autoimmune myocarditis. Chinese Medical Journal 117(8): 1253-1255
Takata, Y.; Blaschke, F.; Okura, T.; Higaki, J.; Hsueh, W.A.; Law, R.E. 2004: PPAR-gamma ligands inhibit transcription of Na+/H+ exchanger-1 via suppression of CCAAT/enhancer-binding protein in HVSMC. Hypertension 43(6): 1351, 1350
Kraft, M.; Riedel, S.; Maaser, C.; Gockel, H.; Heidemann, J.; Kucharzik, T.; Domschke, W.; Luegering, N. 2001: PPAR-gamma ligands potently inhibit CXC-chemokine secretion in colonic epithelial cell lines. Gastroenterology 120(5 Suppl 1): A 319
Eibl, G.; Reber, H.A.; Wente, M.N.; Hines, O.J. 2002: PPAR-gamma mediates the nimesulide-induced increase in VEGF production in human pancreatic cancer cells. Gastroenterology 122(4 Suppl 1): A-489
D.L.B. Elwood, F.; Chen, J.L.; Cushing, T.D.; Flygare, J.A.; Houze, J.B.; Jaen, J.C.; Mcgee, L.R.; Miao, S.C.; Rubenstein, S.M.; Kearney, P.C. 2001: PPAR-gamma modulators. Official Gazette of the United States Patent and Trademark Office Patents 1244(2)
Brunn, G.; Hammermann, R.; Wenzel, F.; Stichnote, C.; Racke, K. 2002: PPAR-gamma receptor agonists inhibit adhesion, and lipopolysaccharide-induced iNOS and L-arginine transport in rat alveolar macrophages. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R43
Padilla, J.; Kaur, K.; Harris, S.G.; Phipps, R.P. 2000: PPAR-gamma-mediated regulation of normal and malignant B lineage cells. Annals of the new York Academy of Sciences 905: 97-109
Duarte, S.F.P.; Barroso, S.G.; Valenca, D.C.T.; Abreu, V.G.; Pimentel, M.M.G.; Francischetti, E.A. 2004: PPAR-gamma2 Pro12Ala and the beta3-adrenergic receptor Trp64Arg polymorphisms in Brazilian subjects Comparison between obese hypertensives and non obese individuals. American Journal of Hypertension 17(5)
Krishnan, S.; Taylor, B.K.; Kadowitz, P.J.; Badr, M. 2003: PPAR-mediated anti-inflammatory effect in vivo a comparison with aspirin and dexamethasone. FASEB Journal 17(4-5): Abstract 152
Gretebeck, R.J.; Mcdaniel, C.; Ji, L.L.; Nickel, K.P.; Belury, M.A. 1999: PPAR-responsive gene expression in liver and muscle of exercise trained rats. FASEB Journal 13(4 Part 1): A418
Komuves, L.; Hanley, K.; Lefebvre, A.M.; Man, M.Q.; Williams, M.; Elias, P.; Auwerx, J.; Feingold, K. 1999: PPAR001alpha-activation promotes epidermal keratinocyte differentiation in vivo. Journal of Investigative Dermatology 112(4): 550
Chen, S.N.; Tsybouleva, N.; Ballantyne, C.M.; Gotto, A.M.J.; Marian, A.J. 2003: PPARG, PPARD and PPARA haplotypes and plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the LCAS population. Circulation 108(17): IV711
Guerre Millo, M.; Rouault, C.; Poulain, P.; Andre, J.; Fruchart, J.C.; Reach, G.; Staels, B. 2001: PPARa-deficiency protects from diet-induced insulin resistance. Diabetes 50(Suppl 2): A272
Delerive, Philippe, Jr; De Bosscher, Karolien, Jr.; Besnard, Sandrine, Jr.; Vanden Berghe, Wim, Jr.; Tedgui, Alain, Sr.; Fruchart, Jean Charles, Sr.; Haegeman, Chris, Sr.; Staels, Bart, Sr 1999: PPARalpha A negative regulator of the vascular inflammatory response. Circulation 100(18): 1; 355
Wahli, W.; Kersten, S.; Devchand, P.; Desvergne, B. 1999: PPARalpha Cross-talk with membrane receptors and control of energy homeostasis. Imura, Hiroo , Kasuga, Masato , Nakao, Kazuwa International Congress Series; Common disease: Genetic and pathogenetic aspects of multifactorial diseases 159-167
Ventre, J.; Wu, M.; Liu, C.; Moller, D.; Mcgarry, D.; Doebber, T. 2003: PPARalpha activation causes paradoxical effects on hepatic malonyl-CoA and lipid metabolism in db/db mice. Diabetes 52(Suppl 1): A8
Rupp, H.; Koenig, H.; Newrzella, P.; Maisch, B. 2001: PPARalpha activator-induced inhibition of TNFalpha expression in pericardial inflammation. European Heart Journal 22(Abstract Suppl): 416
Marx, N.; Mackman, N.; Schonbeck, U.; Yilmaz, N.; Hombach, V.; Libby, P.; Plutzky, J. 2000: PPARalpha activators regulate tissue factor expression in human monocytes. Journal of Submicroscopic Cytology and Pathology 32(3): 414
Diep, Q.N.; Cohn, J.S.; Schiffrin, E.L. 2001: PPARalpha activators, but not PPARgamma activators, decrease cholesterol concentrations in angiotensin II-infused rats. Circulation 104(17): 2; 22-II 23
Xu, J.; Chang, V.; Joseph, S.; Bassilian, S.; Saad, M.; Lee, W.N.P.ul; Kurland, I.J. 2003: PPARalpha affects pathways of gluconeogenesis from glycerol. FASEB Journal 17(4-5): Abstract 374
Shimomura, K.; Shimizu, H.; Uehara, Y.; Mori, M. 2001: PPARalpha agonist, fenofibrate, modulates betacell function. Diabetes 50(Suppl 2): A529
Racke, M.K.; Hussain, R.Z.; Northrup, S.; Diab, A.; Lovett Racke, A.E. 2003: PPARalpha agonists as therapy for autoimmune demyelination. Neurology 60(5 Suppl 1): A219
Teissier, E.; Nohara, A.; Chinetti, G.; Fruchart, J.C.; Shah, A.; Staels, B. 2004: PPARalpha agonists induce generation of hydrogen peroxide in human macrophages via NADPH oxidase stimulation. Mediators of Inflammation 13(1): 66
Liu, C.; Wu, M.; Ventre, J.; Doebber, T. 2003: PPARalpha agonists markedly increase hepatic levels of unsaturated long chain acyl-CoA species and insulin sensitivity in db/db mice. Diabetes 52(Suppl 1): A8
Hermanowski Vosatka, A.; Mundt, S.S.; Loving, V.A.; Lu, M.; Gerhold, D.; Chen, Y.; Elbrecht, A.; Wu, M.; Doebber, T.; Kelly, L.; Milot, D.; Guo, Q.; Wang, A.; Ippolito, M.; Chao, Y.S.; Wright, S.D.; Thieringer 2000: PPARalpha agonists reduce the expression of 11betaHSD1 in the liver. Journal of Endocrinology 164(Suppl ): P283
Wu, M.; Ventre, J.; Liu, C.; Doebber, T. 2003: PPARalpha agonists stimulate a futile cycle of increased fatty acid synthesis and oxidation in liver. Diabetes 52(Suppl 1): A8-A9
Chinetti, G.; Lestavel, S.; Remaley, A.; Neve, B.; Torra, I.P.; Minnich, A.; Jaye, M.; Duverger, N.; Brewer, H.B.; Fruchart, J.C.; Clavey, V.; Staels, B. 2000: PPARalpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABC-1 pathway. Circulation 102(18): 2; 311
Marx, N.; Kehrle, B.; Grueb, M.; Plutzky, J. 2000: PPARalpha and PPARgamma activators inhibit TH1-cytokine expression in human T4-cells. Circulation 102(18): 2; 175
Miyahara, T.; Motomura, K.; Anania, F.A.; Tsukamoto, H. 1999: PPARalpha and PPARgamma ligands inhibit hepatic stellate cell activation. Hepatology 30(4 Part 2): 412A
Teissier, E.; Chinetti, G.; Staels, B. 2002: PPARalpha but not PPARgamma agonists induce generation of hydrogen peroxide in human macrophages. Circulation 106(19): II261
Portilla, D.; Kurden, R.; Kaushal, G.P. 2002: PPARalpha but not PPARgamma ligands protect against Cisplatin-induced renal tubular epithelial cell injury. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 138A-139A
Reijngoud, D.J.; Bandsma, R.; Van Dijk, T.; Kok, T.; Staels, B.; Kuipers, F. 2003: PPARalpha deficiency does not affect gluconeogenesis but induces partitioning towards hepatic glycogen stores in mice. Diabetes 52(Suppl 1): A60
Makaula, S.; Lopaschuk, G.D.; Sack, M.N.; Essop, F. 2002: PPARalpha induction of cardiac acetyl-CoA carboxylase expression is nullified by post-translational regulation in response to nutritional flux. Circulation 106(19): II196
Kintscher, U.; Wakino, S.; Bruemmer, D.; Kim, S.; Law, R.E. 2001: PPARalpha ligands inhibit TGF-beta1-induced, SP1-mediated beta5-integrin transcription in vascular smooth muscle cells. Circulation 104(17): 2; 267-II 268
Ghosh, S.S.; Gehr, T.W.B.; Fakhry, I.; Sica, D.A.; Schoolwerth, A.C. 2002: PPARalpha ligands inhibit mouse mesangial cell proliferation. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 295A
Portilla, D.; Dai, G.; Mcclure, T.; Kurden, R.; Kaushal, G.P. 2001: PPARalpha ligands protect against cisplatin induced proximal tubule cell death by inhibiting Caspase 3 activation and preventing LDH release. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 804A
Campbell, F.M.; Kozak, R.; Wagner, A.; Altarejos, J.Y.; Dyck, J.R.B.; Belke, D.D.; Severson, D.L.; Weinheimer, C.J.; Courtois, M.R.; Kelly, D.P.; Lopaschuk, G.D. 2001: PPARalpha regulates cardiac energy metabolism by controlling malonyl CoA concentrations in the heart. Journal of Molecular and Cellular Cardiology 33(6): A164
Linden, D.; Lindberg, K.; Oscarsson, J.; Li, L.; Asp, L.; Boren, J.; Wiklund, O.; Olofsson, S.O. 2002: PPARalpha regulates the secretion and size of VLDL by decreasing the post-ER pre-secretory proteolysis of apoB-100. European Heart Journal 23(Abstract Suppl): 565
Tordjman, K.M.; Coleman, T.; Zhang, F.; Semenkovich, C.F. 1999: PPARalpha suppresses insulin secretion. Diabetes 48(Suppl 1): A3-A4
Roduit, R.; Gremlich Irrausch, S.; Peyot, M.; Desvergnes, B.; Prentki, M.; Wahli, W. 2002: PPARalpha, lipid partitioning and glucose stimulated insulin secretion A study in PPARalpha-deficient mice. Diabetologia 45(Suppl 2): A 86
Kroetz, D.L.; Waddell, D.S.; Schweizer, A.; Bianchi, P.; Ladouce, N.; Pineau, T. 1999: PPARalpha-dependent induction of renal CYP4A expression by fasting. Clinical Pharmacology and Therapeutics 65(2): 188
Gray, J.P.; Vanden Heuvel, J.P. 2003: PPARalpha-dependent regulation of tumor suppressors p19 and c-Abl by peroxisome proliferators and phorbol esters. Toxicological Sciences 72(S-1): 176
Kuwada, S.K.; Scaife, C.L.; Li, X.; Daynes, R.A. 1999: PPARalphaactivation decreases COX2 levels and tumorigenicity in human colon cancer cells. Gastroenterology 116(4 Part 2): A447
Rost, T.H.; Gudbrandsen, O.A.; Tronstad, K.J.; Mellgren, G.; Berge, R.K. 2004: PPARdelta activation in relation to reduction of adipose tissue. Chemistry and Physics of Lipids 130(1): 74
Bastin, J.; Bonnefont, J.P.; Munnich, A.; Djouadi, F. 2003: PPARdelta agonist corrects fatty acid oxidation in CPT2-deficient myoblasts. American Journal of Human Genetics 73(5): 628
Ding, G.; Mou, Y.; Cheng, L.; Din, Q.; Wu, H.; Woods, D.; Huang, Y.; Yang, Q. 2003: PPARdelta inhibits cardiac TNFalpha expression in response to inflammatory stimuli in vivo and in vitro. Circulation 108(17): IV91
Gupta, R.A.; Radhika, A.; Shao, J.; Sheng, H.; Dey, S.K.; Dubois, R.N. 2000: PPARdelta is a putative downstream receptor of COX-2 derived prostacyclin during colorectal carcinogenesis. Gastroenterology 118(4 Suppl 2 Pt 1): AGA A681
Fajas, L.; Rocchi, S.; Auwerx, J. 2000: PPARgamma A versatile metabolic regulator. Hormone Research 53(Suppl 2): 3
Fajas, L. 2002: PPARgamma From cell proliferation to adipocyte differentiation. International Journal of Obesity 26(Suppl 1): S159
Konopleva, M.; Lapillonne, H.; Lee, R.M.; Wang, R.Y.; Tsao, T.; Mcqueen, T.; Andreeff, M. 2002: PPARgamma Ligand CDDO Induces Apoptosis in Leukemias Via Multiple Apoptosis Pathways. Blood 100(11): Abstract No. 2209
Galli, A.; Svegliati Baroni, G.; Mello, T.; Salzano, R.; Ceni, E.; Crabb, D.; Casini, A. 2001: PPARgamma activation by antidiabetic thiazolidinediones reduces liver fibrosis and hepatic stellate cells activation in vivo. Journal of Hepatology 34(Suppl 1): 92
Scheuermann Freestone, M.; Madsen, P.L.; Buckingham, R.; Styles, P.; Neubauer, S.; Clarke, K. 2003: PPARgamma activation improves cardiac energy metabolism in patients with type 2 diabetes mellitus. Circulation 108(17): IV60
Didion, S.P.; Ryan, M.J.; Sigmund, C.D.; Faraci, F.M. 2003: PPARgamma activation improves endothelial function in type II diabetes. FASEB Journal 17(4-5): Abstract 569
Gupta, R.A.; Krishna, U.S.; Gaus, K.; Shappell, S.; Israel, D.A.; Tham, K.T.; Dubois, R.N.; Peek, R.M.Jr 2002: PPARgamma activation inhibits Helicobacter pylori-induced host inflammatory responses in vivo and in vitro. Gastroenterology 122(4 Suppl 1): A 11
Takata, Y.; Kitami, Y.; Yang, Z.H.; Nakamura, M.; Watanabe, S.; Okura, T.; Hiwada, K. 2000: PPARgamma activation inhibits IL-6 and PDGF alpha-receptor expression via a nuclear cofactor C/EBPdelta in vascular smooth muscle cells. Hypertension 36(4): 679
Bagi, Z.; Koller, A.; Kaley, G. 2003: PPARgamma activation restores NO-mediated dilations of coronary arterioles in type 2 diabetes mellitus. Circulation 108(17): IV80
Brown, K.K.; Winegar, D.A.; Franklin, M.C.; Michaud, E.J.; Knapp, F.F.J. 2003: PPARgamma activation restores insulin sensitivity, reduces triacylglycerol accumulation and improves glucose uptake in the diabetic mouse heart in vivo. Circulation 108(17): IV61
Zheng, F.; Fornoni, A.; Elliot, S.J.; Guan, Y.F.; Breyer, M.D.; Striker, L.J.; Striker, G.E. 2001: PPARgamma activation suppresses TGF-beta mediated type I collagen expression in mesangial cells. Diabetes 50(Suppl 2): A74
Brown, K.; Novak, P.; Oliver, W., J.; Saintillan, Y.; Mayoux, E. 2001: PPARgamma activation with farglitazar decreased blood pressure in conscious instrumented normal and spontaneously hypertensive rats. Diabetes 50(Suppl 2): A408
Brown, K.; Novak, P.; Oliver, W.; Saintillan, J.; Mayoux, E. 2001: PPARgamma activation with farglitazar decreased blood pressure in normal and spontaneously hypertensive rats. Diabetologia 44(Suppl 1): A272
Ishibashi, M.; Hiasa, K.I.; Inoue, S.; Kataoka, C.; Ni, W.; Usui, M.; Zhao, Q.W.; Ichiki, T.; Egashira, K. 2001: PPARgamma activation with pioglitazone prevents coronary arteriosclerosis through inhibition of inflammation by downregulation of monocyte CCR2 in a rat model of chronic blockade of nitric oxide synthesis. Circulation 104(17): 2; 267
Brown, K.K.; Franklin, M.C.; Binz, J.G.; Henke, B.R.; Winegar, D.A.; Taj, S.; Bahirwani, R.; Michaud, E.J.; Jones, B.H.; Beets, A.L.; Knapp, F.F.Jr 2001: PPARgamma activator GI251929 alters glucose and lipid uptake and metabolism Cardiac gene expression and tracer studies with -BMIPP and -2-FDG. Journal of Molecular and Cellular Cardiology 33(6): A163
Yang, Z.H.; Takata, Y.; Nakamura, M.; Mori, S.; Jiang, Y.N.; Okura, T.; Kitami, Y.; Hiwada, K. 2000: PPARgamma activator inhibits IL-6-induced C/EBPdelta expression in vascular smooth muscle cells. American Journal of Hypertension 13(4 Part 2): 153A
Mach, F.A.; Marx, N.; Sauty, A.; Luster, A.D.; Plutzky, J. 1999: PPARgamma activators selectively inhibit the IFNgamma-inducible CXC chemokines IP-10, Mig, and I-TAC in endothelial cells. Circulation 100(18): 1; 615
Swan, T.L.; Vandevoort, C.A.; Chaffin, C.L. 2003: PPARgamma activity and expression during luteinization of the rat ovary. Biology of Reproduction 68(Suppl 1): 305-306
Matthieu, J.M.; Honegger, P.; Pershadsingh, H.A.; Feinstein, D.L.; Duvanel, C.B.sson 2002: PPARgamma agonist hinders anti-MOG mediated demyelination in vitro. Journal of Neurochemistry 81(Suppl 1): 36
Kitamura, S.; Miyazaki, Y.; Hiraoka, S.; Nagasawa, Y.; Toyota, M.; Kiyohara, T.; Shinomura, Y.; Matsuzawa, Y. 2000: PPARgamma agonist inhibits cell growth of H-ras transformed rat intestinal epithelial cells through the suppression of transcriptional activities of AP-1 and Ets. Gastroenterology 118(4 Suppl 2 Pt 1): A220
Kitamura, S.; Miyazaki, Y.; Shinomura, Y.; Kondo, S.; Kanayama, S.; Matsuzawa, Y. 1999: PPARgamma agonist inhibits interleukin-8 production by the human colon epithelial cell line HT-29. Gastroenterology 116(4 Part 2): A896
Welbourne, T.; Su, G.; Coates, G.; Routh, R.; Mccarthy, K.; Battarbee, H. 2002: PPARgamma agonist troglitazone induces cellular acidosis. FASEB Journal 16(5): A1170
Robbins, M.E.; Zhao, W.; Zhang, D. 2003: PPARgamma agonists abrogate oxidative stress-mediated upregulation of mesangial cell PAI-1 expression. Journal of the American Society of Nephrology 14(Abstracts Issue): 642A
Verma, S.; Badiwala, M.V.; Li, S.H.; Mickle, D.A.G. 2002: PPARgamma agonists counter the atherogenic effects of CRP A novel observation. Circulation 106(19): II625
Bright, J.J.; Natarajan, C.; Large, E. 2001: PPARgamma agonists prevent EAE by inhibiting IL-12 signaling through JAK-STAT pathway in T cells. FASEB Journal 15(5): A1039
Toyota, M.; Miyazaki, Y.; Kitamura, S.; Nagasawa, Y.; Hiraoka, S.; Kiyohara, T.; Shinomura, Y.; Matsuzawa, Y. 2000: PPARgamma and RXR synergistically inhibit the expression of cyclin D1 and suppress the growth of pancreatic cancer cells. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1111
Weller, S.G.; Karnes, W.E.Jr; Copland, J.A.; Morrow, J.D.; Chinery, R. 2001: PPARgamma and beta-catenin interact to regulate COX-2 expression induced by insulin in HT-29 colon cancer cells. Gastroenterology 120(5 Suppl 1): A 60
Samid, D.; Wells, M.; Greene, M.; Shen, W.; Strub, S.; Palmer, C.; Thibault, A. 1999: PPARgamma as a novel target in differentiation therapy Identification of aromatoids with clinical activity as new ligands. Proceedings of the American Association for Cancer Research Annual Meeting 40: 616
Hazra, S.; Chatterjee, V.K.ishna K.; Rippe, R.A.; Tsukamoto, H. 2002: PPARgamma dependent regulation of hepatic stellate cells. Hepatology 36(4 Part 2): 255A
Nicholas, S.B.; Kawano, Y.; Wakino, S.; Hsueh, W.A. 2000: PPARgamma expression and function in mesangial cells Implication for renal disease. Hypertension 36(4): 679
Tanaka, T.; Matono, S.; Yamana, H.; Sueyoshi, S.; Toh, U.; Fujita, H.; Shirouzu, K. 2001: PPARgamma expression in esophageal cancer and effect of PPARgamma ligands. European Journal of Cancer 37(Suppl 6): S126
Iso, K.; Nohira, T.; Itokazu, I.; Takayama, M. 2000: PPARgamma expression in the human placenta. Placenta 21(7): A 17
Jarvis, M.C.; Bibby, M.C.; Baokbah, T.A.; Hussain, N.B.; Ganta, S.; Thompson, M.J. 2000: PPARgamma expression in the normal and neoplastic human bladder and prostate and its potential as a novel therapeutic target. British Journal of Cancer 83(Suppl 1): 23
Hevener, A.L.; He, W.; Barak, Y.; Evans, R.; Olefsky, J. 2001: PPARgamma heterozygous gene deletion rescues the insulin resistant phenotype in male mice. Diabetes 50(Suppl 2): A244-A245
Lazar, M.A. 2003: PPARgamma in adipocyte differentiation and metabolism. FASEB Journal 17(4-5): Abstract 356
Xiong, S.; Miyahara, T.; Schrum, L.W.; Rippe, R.A.; Yee, H., J.; Yavrom, S.M.; She, H.; Willson, T.M.; Tsukamoto, H. 2000: PPARgamma inhibits hepatic stellate cell collagen gene expression. Hepatology 32(4 Pt 2): 185A
Bright, J.J.; Natarajan, C.; Muthian, G.; Barak, Y.; Evans, R.M. 2003: PPARgamma is a physiological regulator of Th1 cell-mediated autoimmune diseases. FASEB Journal 17(7): C276
Milstone, D.S.; O'donnell, P.E.; Davis, V.M.; Mortensen, R.M.; Rosen, E.; Stavrakis, G. 2001: PPARgamma is expressed and regulates placental development and trophoblast differentiation in both humans and mice. FASEB Journal 15(4): A583
Servidei, T.; Morosetti, R.; Stoler, A.B.; Segni, G.; Koeffler, H.P.; Mastrangelo, R. 2002: PPARgamma is modulated in response to PGJ2 in human glioblastoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 43: 121
Lupi, R.; Del Guerra, S.; Marselli, L.; Bugliani, M.; Boggi, U.; Mosca, F.; Marchetti, P.; Del Prato, S. 2002: PPARgamma ligand-specificity in the modulation of insulin release from isolated human islets in response to fatty acid incubation. Diabetologia 45(Suppl 2): A 161
Girnun, G.D.; Spiegelman, B.M. 2003: PPARgamma ligands: taking Ppart in chemoprevention. Gastroenterology 124(2): 564-567
Lu, W.J.; Guan, Y.; Redha, R.; Zhang, Y.; Breyer, M. 2003: PPARgamma ligands activate Na+ absorption by the inner medullary collecting duct. FASEB Journal 17(4-5): Abstract 585
Saubermann, L.J.; Wada, K.; Zhao, S.; Nakajima, A.; Blumberg, R.S.; Matsuhashi, N. 2001: PPARgamma ligands are preventive in a murine model of colitis in a dose and cytokine dependent fashion. Gastroenterology 120(5 Suppl 1): A 690
Fahmi, H.; Pelletier, J.-P.; Martel-Pelletier, J. 2002: PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. Journal of Rheumatology 29(1): 3-14
Collins, A.R.; Noh, G.; Hsueh, W.A.; Law, R.E. 2001: PPARgamma ligands attenuate angiotensin-II accelerated atherosclerosis in male low density receptor deficient mice. Diabetes 50(Suppl 2): A72-A73
Takano, H.; Asakawa, M.; Toyozaki, T.; Nagai, T.; Saito, T.; Masuda, Y. 1999: PPARgamma ligands inhibit LPS-induced expression of TNFalpha in cardiac myocytes. Circulation 100(18): 1; 429
Wakino, S.; Collins, A.R.; Kintscher, U.; Kim, S.; Yin, F.; Noh, G.; Moller, D.E.; Hsueh, W.A.; Law, R.E. 2001: PPARgamma ligands inhibit angiotensin II-induced Egr-1 expression in vivo and in vitro. Circulation 104(17): 2; 180
Su, C.G.; Wen, X.; Keilbaugh, S.A.; Wu, G.D. 2000: PPARgamma ligands inhibit immune-stimulated phosphorylation of I kappa B alpha via a mechanism that requires the activation of gene transcription and new protein synthesis. Gastroenterology 118(4 Suppl 2 Pt 1): AGA A811
Yamamoto, K.; Ohki, R.; Lee, R.T. 2000: PPARgamma ligands inhibit mechanically-induced hypertrophy in cardiac myocytes. Circulation 102(18): 2; 70-II 71
Farrow, B.; Hashimoto, K.; Iwamura, T.; Evers, B.M.rk 2002: PPARgamma ligands inhibit the phosphatidylinositol-3 kinase pathway and pancreatic cancer invasion in vitro. Gastroenterology 122(4 Suppl 1): A-493-A-494
Yasugi, E.; Horiuchi, A.; Okuma, E.; Nakatsu, M.; Saeki, K.; Uemura, I.; You, A. 2003: PPARgamma ligands promote human leukemia NB4 cells to myeloid differentiation. Developmental Biology 259(2): 511
Osawa, E.; Nakajima, A.; Sekihara, H.; Nakagama, H. 2002: PPARgamma ligands suppress the formation of ACF and colon tumors induced by azoxymethane in mice. Proceedings of the American Association for Cancer Research Annual Meeting 43: 75
Subbaramaiah, K.; Lin, D.T.; Dannenberg, A.J. 2001: PPARgamma ligands suppress the transcriptional activation of cyclooxygenase-2. Proceedings of the American Association for Cancer Research Annual Meeting 42: 550
Konopleva, M.Y.; Tsao, T.; Lapillonne, H.F.; Sudarikov, A.; Mcqueen, T.; Hu, W.X.; Monaco, G.; Wang, R.Y.; Belmont, J.; Sporn, M.B.; Andreeff, M. 2002: PPARgamma nuclear receptor as a novel molecular target in leukemia therapy. Proceedings of the American Association for Cancer Research Annual Meeting 43: 955-956
Coste, A.; Authier, H.; Balard, P.; Cassaing, S.; Linas, M.D.; Bernad, J.; Lepert, J.C.; Dubourdeau, M.; Pipy, B. 2004: PPARgamma promotes macrophage mannose receptor gene expression by IL-13 consequences in the control of gastrointestinal candidosis in normal and immunodeficient RAG- 2-/- mice. Mediators of Inflammation 13(1): 57
Hazra, S.; She, H.; Xiong, S.; Rippe, R.A.; Tangkjvanich, P.; Yee, H., J.; Tsukamoto, H. 2001: PPARgamma regulation of hepatic stellate cells. Hepatology 34(4 Pt 2): 444A
Galli, A.; Crabb, D.; Price, D.; Ceni, E.; Salzano, R.; Surrenti, C.; Casini, A. 1999: PPARgamma transcriptional regulation is involved in PDGF-induced mitogenesis of activated human hepatic stellate cells. Journal of Hepatology 30(Suppl 1): 89
Koutnikova, H.; Auwerx, J. 2002: PPARgamma, an X-ceptor for Xs. Annals of the new York Academy of Sciences 967: 28-33
Kwak, B.R.; Myit, S.; Mulhaupt, F.; Mach, F. 2000: PPARgamma, but not PPARalpha, activators inhibit MHC-II expression in atheroma-associated cells. Circulation 102(18): 2; 66
Hammarstedt, A.; Smith, U. 2001: PPARgamma, but not PPARalpha, ligands increase IRS-1 gene and protein expression in L6 muscle cells. Diabetes 50(Suppl 2): A409
Marx, N.; Rautzenberg, K.; Jung, A.; Grueb, M.; Bach, H.; Wautier, M.P.; Wautier, J.L. 2002: PPARgamma-activators inhibit the expression of the receptor for advanced glycation endproducts in human endothelial cells, a new approach to limit diabetic angiopathy. Circulation 106(19): II217
Katayama, K.; Wada, K.; Nakajima, A.; Tachibana, M.; Mizuguchi, H.; Hayakawa, T.; Ariyama, T.; Nakagawa, S.; Kadowaki, T.; Kamisaki, Y.; Blumberg, R.S.; Mayumi, T. 2003: PPARgamma-gene therapy of inflammatory bowel disease. Journal of Pharmacological Sciences 91(Suppl I): 167P
Goetze, S.; Bungenstock, A.; Eilers, F.; Kintscher, U.; Stawowy, P.; Graf, K.; Law, R.E.; Grafe, M. 2001: PPARgamma-ligands block leptin-induced endothelial cell migration by inhibiting Akt. Circulation 104(17): 2; 124
Goetze, S.; Stawowy, P.; Kintscher, U.; Blaschke, F.; Spencer Haensch, C.; Graf, K.; Fleck, E.; Graefe, M. 2002: PPARgamma-ligands inhibit endothelial cell migration mediated by different chemoattractants via inhibition of Akt and eNOS. European Heart Journal 23(Abstract Suppl): 9
Oyama, Y.ko; Akuzawa, Nobuhiro; Endo, Michiko; Kurabayashi, Masahiko 2000: PPARgamma-ligands mediate gene-specific regulation in human monocyte/macrophage cells, THP-1 cells. Circulation 102(18): 2; 294
Zander, T.; Kraus, J.A.; Schlegel, U.; Feinstein, D.L.; Klockgether, T.; Heneka, M.T. 2001: PPARgamma-mediated apoptotic cell death in human and rat glioma cell lines A new therapeutic strategy?. Neurology 56(8 Suppl 3): A480-A481
Schinner, S.; Dellas, C.; Heinlein, C.; Chang, C.; Knepel, W. 2001: PPARgamma-mediated inhibition of glucagon gene transcription by the oral antidiabetic agents thiazolidinediones. Naunyn-Schmiedeberg's Archives of Pharmacology 363(4): R20
Farrow, B.; Evers, B.M. 2003: PPARgamma-mediated inhibition of pancreatic cancer invasion by increased adhesion between pancreatic cancer cells and tumor-derived fibroblasts. Pancreas 27(4): 380
Blueher, M.; Paschke, R. 2001: PPARgamma-polymorphisms in obese patients with insulin resistance. Experimental and Clinical Endocrinology and Diabetes 109(Suppl 1): S48
Gonzalez Sanchez, J.L.; Martinez Larrad, M.T.; Pladevall, M.; Vega, S.; Horcajo, P.; Gabriel, R.; Serrano Rios, M. 2001: PPARgamma2 Pro12Ala polymorphism and glucose tolerance, insulin resistance index , insulin, proinsulin, leptin levels and obesity in the general population of Spain. Diabetes 50(Suppl 2): A234-A235
Jacob, S.; Brechtel, K.; Rett, K.; Machann, J.; Koch, M.; Nielsen, M.; Loeblein, K.; Becker, R.; Maerker, E.; Volk, A.; Deninger, M.; Renn, W.; Machicao, F.; Claussen, C.D.; Schick, F.; Haering, H.U. 1999: PPARgamma2 amino acid polymorphism Pro12Ala alters the correlation between intramyocellular lipid content and insulin sensitivity in offspring of type 2 diabetes patients. Diabetologia 42(Suppl 1): A44
Rodriguez, E.; Ribot, J.; Palou, A. 2003: PPARgamma2 expression in response to cafeteria-diet feeding Gender- and depot-specific effects. International Journal of Obesity 27(Suppl 1): S62
Oliver, W.R.J.; Wilson, J.G.; Rafferty, S.; Alexander, T.; Hansen, B.C.; Sternbach, D.D. 2003: PPARpan improves glycemic control without weight gain or hemodilution Nonclinical data in diabetic rodents and non-human primates. Diabetologia 46(Suppl 2): A 302
Bocher, V.; Pineda-Torra, I.; Fruchart, J.-C.; Staels, B. 2002: PPARs: transcription factors controlling lipid and lipoprotein metabolism. Annals of the new York Academy of Sciences 967: 7-18
Latruffe, N.; Malki, M.C.; Nicolas Frances, V.; Jannin, B.; Clemencet, M.C.; Hansmannel, F.; Passilly Degrace, P.; Berlot, J.P. 2001: PPARs as physiological sensors of fatty acid metabolism molecular regulation in peroxisomes. Biochemical Society Transactions 29(1): A5
Plutzky, J. 2003: PPARs as therapeutic targets Reverse cardiology?. Science 302(5644): 406-407
Staels, B.; Delerive, P.; De Bosscher, K.; Vanden Berghe, W.; Fruchart, J.C.; Haegeman, G. 2001: PPARs mediated regulation of inflammatory pathways. Clinical Rheumatology 20(5): 409
Gallant, D.; Aguirre, J. 1999: PPD positivity in high risk pediatric population in Albuquerque, New Mexico. Journal of Investigative Medicine 47(2): 86A
Parkansky, I.; Lee, J.; Amer, H.; Elivera, H.; Ahmed, Z. 2003: PPD skin testing in hemodialysis units How often to screen?. Journal of the American Society of Nephrology 14(Abstracts Issue): 719A
Miller, C.; Trok, B.; Barnett, V.A. 1999: PPDM titration of active crossbridges Relationship between isometric force and unloaded shortening velocity. Biophysical Journal 76(1 Part 2): A160
Kobayashi, M.; Chikashima, H.; Takamatsu, K. 2000: PPEF2 regulates mAChR-mediated ERK activation. Neuroscience Research Suppl (24): S66
Andersen, J.T.; Ehrlich, S.D. 2001: PPGPP synthetase and expression systems for improved production of protein of interest. Official Gazette of the United States Patent and Trademark Office Patents 1251(4)
Evans, J.C.; Trembath, R.C. 2002: PPHGENESNET A database of BMPR2 mutations. Journal of Medical Genetics 39(Suppl 1): S67
Alonso Aguirre, P.A. 2002: PPi test and endoscopy in GERD. Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 94(2): 88-97
Goldstein, J.L.; Huang, B.; Collis, C.M.; Lukasik, N.L. 2000: PPI based healing of NSAID associated ulcers in patients continuing NSAIDs. American Journal of Gastroenterology 95(9): 2452
Ludewig, K.; Leumann, L.R.; Etzensberger, M.; Vollenweider, F.X. 2000: PPI deficits in antipsychotic-treated, chronic schizophrenic patients. European Neuropsychopharmacology 10(Suppl 3): S318
Brunner, G.H.G.; Athmann, C.; Harke, U. 2002: PPI maintenance therapy in patients with liver cirrhosis. Gastroenterology 122(4 Suppl 1): A 582
Kline, M.; Morales, O. 2002: PPI therapy for 24 hour pH negative heartburn. Gastroenterology 122(4 Suppl 1): A-194
Ryoo, E.; Chang, J.Y.; Ko, J.S.; Seo, J.K. 2000: PPI-based triple versus quadruple therapy for eradicating Helicobacter pylori infections in children. JPGN 31(Suppl 2): S217-S218
Suzuki, M.; Suzuki, H.; Kitahora, T.; Ono, H.; Kawaguchi, C.; Suzuki, K.; Ishii, H. 2000: PPI-treatment attenuates the production of neutrophil-derived oxidant, not interleukin-8 content in Hpylori-infected antral mucosa. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1311
D.M.rio, F.; Dal Bo', N.; Pilotto, A.; Battaglia, G.; Salandin, S.; Franceschi, M.; Mastropaolo, G.; Vigneri, S.; Savarino, V.; Rugge, M. 2000: PPIs plus H2-antagonists for non-responders GERD patients A rescue therapy?. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1227
Nicholson, T.; Ingram, P.; Barman, P.; Murray, I.A. 2004: PPIs, TTOs, and nice guidelines Determining how to reduce prescribing costs. Gut 53(Suppl 3): A22-A23
Zhang, Y.; Neelamegham, S. 2003: PPLATE: a computer program for analysis of parallel-plate flow chamber experimental data. Journal of Immunological Methods 278(1-2): 319-321
Jiang, X.; Kong, W.; Farguharson, M.; Mercer, W.E. 2003: PPM1D phosphatase is associated with doxorubicin resistance in human breast cancer cells that harbored wild type p53. Proceedings of the American Association for Cancer Research Annual Meeting 44: 547-548
Wolinsky, J.; Lublin, F.; Birnbaum, G.; Polman, C.; Arnason, B.; Filippi, M.; Miller, D.; Barkhof, F.; Simon, J.; Edan, G.; Hawkins, S.; Noseworthy, J.; Duquette, P.; Cook, S.; Mattson, D.; Metz, L.; Thompson, A.; Sorensen, P.S.elberg 2004: PPMS roundtable discussion. Multiple Sclerosis 10(3, Suppl S): S90-S96, S81
Brils, J. 2003: PPP perspective on sediment quality in relation to contamination. Journal of Soils and Sediments 3(2): 63
Evans, G.A.; Wang, S.S.; Esplin, E.D.; Li, J.L.; Huang, L. 2004: PPP2R1B is a tumor suppressor. Official Gazette of the United States Patent and Trademark Office Patents 1283(1)
Newaz, M.; Yousefipour, Z.; Oyekan, A. 2004: PPPAR gamma Induction Improves Vascular Reactivity and Renal Function In Glycerol-Induced Acute Renal Failure. FASEB Journal 18(4-5): Abstract 832
Bueno, H. 2000: PPRIMM75 project Ten years of research in the prognosis of acute myocardial infarct in the elderly. Revista Espanola de Geriatria y Gerontologia 35(2): 95-101
Duwe, J.; Zisch, A.H.; Karrer, L.; Khabiri, E.; Napoli, A.; Hubbell, J.A.; Schaffner, T.; Hess, O.M.; Carrel, T.; Kalangos, A.; Walpoth, B.H. 2003: PPS-PEG surface coating to reduce thombogenicity of small diameter ePTFE vascular grafts. International Journal of Artificial Organs 26(7): 592
Ghaderi, A.; Gharesi Fard, B.; Talei, A.; Vasei, M.; Modjtahedi, H. 2001: PPrognostic value of estrogen-progesterone receptors , EGFR and HER-2 in breast cancer. British Journal of Cancer 85(Suppl 1): 48
Schneider, G.B.; Bui, D.T.; Grecco, K.J. 2002: PQCT analysis of the anabolic effects of a group of novel small peptides on bone in intact adult rats. Journal of Bone and Mineral Research 17(Suppl 1): S377
Meta, M.D.; Olivera, M.I.; Schneider, P.; Bozzini, C.E.; Alippi, R.M. 1999: PQCT assessed mandibular bone quality in rats after dietary restriction during the suckling period. Journal of Bone and Mineral Research 14(Suppl 1): S518
Priemel, M.; Schmidt, C.; Kohler, T.; Rueger, J.M.; Mueller, R.; Amling, M.; Eckstein, F. 2002: PQCT is a precise and accurate tool for skeletal analysis of mice in vivo. Journal of Bone and Mineral Research 17(Suppl 1): S412
Gonzales, J.; Grubman, E.; Kocovic, D.Z.; Pavri, B.B. 1999: PR and RR interval variability Comparison in normals, congestive heart failure and inappropriate sinus tachycardia. Circulation 100(18): 1; 453
Huang, S. 2000: PR domain peptides. Official Gazette of the United States Patent and Trademark Office Patents 1234(5)
De La Briolle, Axel Champagne; Leclercq, Christophe; Sebille, Veronique; Carre, Francois; De Place, Christian; Mabo, Philippe; Daubert, Jean Claude 2004: PR interval prolongation but not QRS widening is an independent factor of functional intolerance in heart failure patients with dilated cardiomyopathy. Journal of the American College of Cardiology 43(5 Suppl A): 119A
Asensio Sanchez, T. 2004: PR-1, a novel class of plant phatogenesis-related proteins involved in food allergy. Journal of Allergy and Clinical Immunology 113(2 Suppl): S153
Bao, J.; Gao, Y.; Li, M.; Abid, M.R.; Aird, W.; Simons, M.; Post, M.J. 2001: PR-39 and PR-11 peptides protect against ischemia-reperfusion injury by inhibition of proteasome mediated Ikappa Balpha degradation. Circulation 104(17): 2; 52
Zheng, L.; Busch, J.L.; Blecha, F.; Ross, C.R. 2002: PR-39, a proline-arginine rich peptide, suppresses inflammatory gene expression. FASEB Journal 16(4): A431
Busch, J.L.; Zheng, L.; Ross, C.R. 2002: PR-39, an antimicrobial peptide, reduces ROS production and neutrophil recruitment in cremaster microvasculature of hypercholesterolemic mice. FASEB Journal 16(4): A85
Kohgo, Y.taka; Fujimoto, Yoshinori; Tanaka, Koji; Suzuki, Masako; Suzuki, Yasuaki; Saito, Hiroyuki; Ohtake, Takaaki 2000: PR-39, endogenous antimicrobial peptide derived from porcine neutrophils is capable binding PI3Kp85 and inhibits cell proliferation and modifies actin bundle structure in K-ras transformed cells. Acta Haematologica (Basel) 103(Suppl 1): 30
Wood, J.G.; Zogleman, B.; Ross, C.R.; Gonzalez, N.C. 2003: PR-39-dependent inhibition of NADPH oxidase promotes mast cell degranulation yet attenuates microvascular inflammatory responses during systemic hypoxia. FASEB Journal 17(4-5): Abstract 818
Huang, S. 2003: PR-domain containing nucleic acids, polypeptides, antibodies and methods. Official Gazette of the United States Patent and Trademark Office Patents 1272(1)
Hoffmann Sommergruber, K. 2002: PR-proteins identified as allergens. Biochemical Society Transactions 30(5): A109
Kristinsson, G.; Flynn, P.; Rapaport, S.; Snyder, M.; Kern, J.H. 2002: PR-segment changes in childhood pericarditis. Journal of Pediatrics 140(3): 378
Plotnikova, J.M.; Gabor, L.; Frederick, A.M. 2002: PR1 and PDF12 have different roles in inhibiting Botrytis infection. Plant Biology (Rockville) : 133
Wieder, E.D.; Kant, S.; Lu, S.; He, Z.; Molldrem, J.J. 2003: PR1 peptide vaccination of myeloid leukemia patients induces PR1-specific CTL with high CCR7 expression. Blood 102(11): 611a-612a
Chen, Z.-Y.; Brown, R.L.; Damann, K.E.; Cleveland, T.E. 2010: PR10 expression in maize and its effect on host resistance against Aspergillus flavus infection and aflatoxin production. Molecular Plant Pathology 11(1): 69-81
Helisch, A.; Wagner, S.; Ziegelhoeffer, T.; Post, M.J. 2002: PR11 PR39 protect against tissue necrosis in mouse hindlimb ischemia model. Circulation 106(19): II112
Schneidewind, J.M.; Ramlow, W.; Tiess, M.; Michelsen, A.; Matic, G.; Patow, W.; Prophet, H.; Hebestreit, G.; Muller, W.; Winkler, R.E. 2000: PR3 ANCA-positive vasculitis treated by immunoadsorption in failed drug therapies. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 97A
Pendergraft, W.F.; Rudolph, E.H.; Jennette, J.C.; Falk, R.J.; Preston, G.A. 2002: PR3 released from neutrophils and monocytes during inflammation enters endothelial cells and cleaves p21 at a signature site independent of that utilized by caspase 3. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 91A
Flores Suarez, L.F.; Flores Munoz, M.; Villa, A.R. 2003: PR3-ANCA serial measurements lack significance as indicative of relapse in Mexican patients with Wegeners granulomatosis. Kidney and Blood Pressure Research 26(4): 276
Lobashevsky, A.; Senkbeil, R.; Shoaf, J.; Rowe, C.; Rhea Tyler, S.; Thomas, J. 1999: PRA analysis using the FLOWPRATM specific test. Human Immunology 60(Suppl 2): S119
Lobashevsky, A.L.; Senkbeil, R.W.; Mink, C.A.; Deierhoi, M.H.; Thomas, J.M. 2002: PRA and alloantibody specificity analysis in renal patients using artificial substrate flow cytometry methods. Human Immunology 63(Suppl 1): S65
Pesoa, S.A.; Bahamondes, S.M.; Borosky, A.I.; Vullo, C.M. 2003: PRA and alloantibody specificity in patients waiting for renal transplantation. Human Immunology 64(Suppl 1): S76
Philogene, M.C.; Green, A.C.; Tardif, G.N.; Ward, W.W. 2001: PRA and specificity comparison between two ELISA assays and standard AHG-CDC for HLA class I antibody. Human Immunology 62(Suppl 1): S139
Page, G.; Van Dam, M.; Heads, A. 2003: PRA or transplantability index What do our clinical colleagues need?. Human Immunology 64(Suppl 1): S30
Tanke, J.; Witvliet, M.; Claas, F.H.J.; Doxiadis, I.I.N. 2001: PRA value is an unreliable parameter for the allocation of cadaveric kidneys. European Journal of Immunogenetics 28(2): 245
Motegi, A.; Olsson, P.; Bera, T.K.; Lee, B.; Pastan, I. 2003: PRAC2, a novel gene expressed in human prostate and prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 255
Arnold, A. 2000: PRAD1 transgenic mice. Official Gazette of the United States Patent and Trademark Office Patents 1237(4)
Monga, S.P.S.; Kennedy, J.; Mishra, B.; Dhanasekaran, D.; Mishra, L. 1999: PRAJA-1, a novel ring finger protein involved in hepatocyte apoptosis is selectively expressed in hepatocyte stem cells. Gastroenterology 116(4 Part 2): A465
Müller, K. 2004: PRAP-computation of Bremer support for large data sets. Molecular Phylogenetics and Evolution 31(2): 780-782
Eldad, Z.; Ho, A.; Jiang, Z. 2002: PRB tumor suppressor as a survival factor Unorthodox pro-life pathways and paradoxical oncogenic effects. International Journal of Molecular Medicine 10(Suppl 1): S29
Larsen, C.-J. 2004: PRB, p53, p16INK4a, senescence and malignant transformation. Bulletin du Cancer 91(5): 399-402
Momose, K.; Kiyosawa, M.; Nemoto, N.; Mori, H.; Mochizuki, M.; Yu, J.J. 2001: PRBS-determined temporal frequency characteristics of VEP in primary open angle glaucoma. IOVS Investigative Ophthalmology and Visual Science 42(4): S788
Pecciarini, L.; Duensing, A.; Lux, M.L.; Chen, C.J.; Xiao, S.; Loda, M.; Pinkus, G.S.; Fletcher, J.A. 2000: PRD1-BF1/BL1MP1 inactivation in progression from small-cleaved to large B cell lymphoma. Laboratory Investigation 80(3): 159A
Pecciarini, L.; Duensing, A.; Lux, M.L.; Chen, C.J.; Xiao, S.; Loda, M.; Pinkus, G.S.; Fletcher, J.A. 2000: PRDI-BF1/BLIMP1 inactivation in progression from small-cleaved to large B cell lymphoma. Laboratory Investigation 80(1): 159A
Duensing, A.; Pecciarini, L.; Lux, M.L.; Chen, C.J.; Xiao, S.; Loda, M.; Pinkus, G.S.; Fletcher, J.A. 2000: PRDM1, a transcriptional repressor of c-myc, is inactivated in B cell neoplasms. Pathology Research and Practice 196(6): 432
Odero, M.D.; Lahortiga, I.; Agirre, X.; Larrayoz, M.J.; Vazquez, I.; Valganon, M.; Olabarria, I.; Novo, F.J.; Calasanz, M.J. 2002: PRDM16/MEL1 Is Not Overexpressed in t -Positive MDS/AML. Blood 100(11): Abstract No. 2081
Zhang, Y.; Emmanuel, N.B.; Kamboj, G.; Chen, J.; Shurafa, M.; Van Dyke, D.L.; Wiktor, A.; Rowley, J.D. 2003: PRDX4, a member of the peroxiredoxin family, is fused to AML1 in an acute myeloid leukemia patient with t translocation. Blood 102(11): 849a-850a
Otsuka, S.; Murao, K.; Sayo, Y.; Namihira, H.; Cao, W.M.; Imachi, H.; Bancroft, C.; Ishida, T. 2001: PREB affects the insulin gene transcription in rat pancreas. Diabetes 50(Suppl 2): A528
Cao, W.; Murao, K.; Sayo, Y.; Ohtsuka, S.; Imachi, H.; Ishida, T. 2003: PREB regulates MCP-1 transcription in response to glucose. Diabetes 52(Suppl 1): A474-A475
Sayo, Y.; Murao, K.; Ohtsuka, S.; Cao, W.; Imachi, H.; Ishida, T. 2003: PREB regulates endothelial nitric oxide synthase transcription in HUVEC. Diabetes 52(Suppl 1): A477
Malo, M.S.; Husain, Z. 2003: PREM a positive selection vector system for direct PCR cloning. Official Gazette of the United States Patent and Trademark Office Patents 1269(2)
Dietrich, S.; Daemon, S.; Widhalm, K. 2003: PRESTO Prevention study of obesity in Austria. International Journal of Obesity 27(Suppl 1): S129
Kataoka, H. 2002: PRF adjustment method and apparatus, and ultrasonic wave imaging apparatus. Official Gazette of the United States Patent and Trademark Office Patents 1264(2)
Sanseverino, W.; Roma, G.; De Simone, M.; Faino, L.; Melito, S.; Stupka, E.; Frusciante, L.; Ercolano, M.R. 2010: PRGdb: a bioinformatics platform for plant resistance gene analysis. Nucleic Acids Research 38(Database Issue): D814-D821
Jayaraman, P.S.; Stifani, S.; Swingler, T.; Bess, K. 2003: PRH and Groucho/TLE proteins co-repress transcription in hematopoietic cells. Blood 102(11): 158b
Rehman, A.; Chahal, M.; Pommier, Y.; Daoud, S. 2003: PRIMA-1 restores the p21 transactivation by tumor suppressor, p53 in breast cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 44: 913
Nahi, H.; Merup, M.; Lehmann, S.; Mollgard, L.; Wiman, C.; Paul, C. 2003: PRIMA-1, a reactivator of mutant p53, induces antileukemic effects in cells from patients with chronic lymphocytic leukemia and acute myeloid leukemia. Blood 102(11): 604a-605a
Kunkler, I.K.; Prescott, R.J.; Williams, L.J.; King, C.C.; Dixon, J.M.; Lindley, R.; Leonard, R.; Cairns, J.; Rodger, A.; Sainsbury, R. 2003: PRIME A randomised trial assessing the role of post-operative breast radiotherapy in older patients. Breast 12(Suppl 1): S44
Blank, R.; Darius, H.; Ries, M.; Vermoehlen, H.; Victor, A.; Meyer, J. 2002: PRIME-ECG mapping in the diagnosis of acute myocardial infarction. European Heart Journal 23(Abstract Suppl): 115
Koch, J. 2002: PRINS Hybridization and primed in situ labeling in one step. Rautenstrauss, Bernd W , Liehr, Thomas Springer Lab Manuals FISH technology 463-472
Koch, J. 2000: PRINS Primed in situ labeling and hybridization in one step. Kessler, Christoph Springer Lab Manuals Nonradioactive analysis of biomolecules Second Edition 407-416
Mayr, B.; Metzler, R.; Korb, H.; Szolgyenyi, W.; Brem, G.; Kleiter, M. 2001: PRINS telomere studies in domestic animals. Annales de Genetique 44(Suppl 1): s44
Mayr, B.; Fuehrer, F.; Bauer, K.; Korb, H. 2003: PRINS-telomere characterization on individual chromosomes of Austrian AI-bulls. Annales de Genetique 46(2-3): 96
Clark, A.D.; Baird, J.W.; Jorgenson, H.; Franklin, I.M.; Holyoake, T.L.; Graham, G.G. 2001: PRIP A novel ES cell derived, haemopoietic stem cell specific Ras effector molecule interacts with PIP 5 kinase and DAG kinase, is homologous to the BCR ABL potentiating adaptor RIN1 and is upregulated in CML. Blood 98(11 Part 1): 756a-757a
Kennedy, E.J.; Moynagh, P.N. 2001: PRISM, a novel mediator of Toll/IL-1 signalling. FASEB Journal 15(4): A209
Yavitz, E. 2002: PRK retreatments after regressed myopic LASIK. Ophthalmology 109(11): 1953-1954
Gobbi, P.G.; Carones, F.; Brancato, R. 1999: PRK ablation algorithms Customized or default corneal curvature?. IOVS Investigative Ophthalmology and Visual Science 40(4): S891
Koons, S.J.; Telfair, W.B.; Rojas, M.L.; Berger, C.; Sanders, R.; Mcdonald, M.B. 2001: PRK study by a mid-infrared solid-state OPO laser in rabbits. IOVS Investigative Ophthalmology and Visual Science 42(4): S610
Johnston, E.W.; El Agha, M.S.; Bowman, R.W.; Cavanagh, H.D.; Mcculley, J.P. 2000: PRK versus LASIK for the treatment of spherical hyperopia using the Visx Star Excimer Laser. IOVS Investigative Ophthalmology and Visual Science 41(4): S691
Gollob, M.H.; Green, M.S.; Tang, A.S.L.; Roberts, R. 2002: PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Current Opinion in Cardiology 17(3): 229-234
Ahmad, F.; Arad, M.; He, H.; Musi, N.; Branco, D.; Xing, Y.; Fujii, N.; Tian, R.; Goodyear, L.J.; Berul, C.I.; Ingwall, J.S.; Seidman, C.E.; Seidman, J.G. 2003: PRKAG2 cardiomyopathy mice demonstrate preserved resting cardiac energy levels and are able to increase cardiac contractility with exercise. Circulation 108(17): IV118-IV119
Sandrini, F.; Matyakhina, L.D.; Bourdeau, I.; Farmakidis, C.; Keil, M.; Kirschner, L.S.; Stratakis, C.A. 2002: PRKAR1A, a regulator of protein kinase A, is mutated in children with Carney Complex and isolated micronodular adrenal hyperplasia. Pediatric Research 51(4 Part 2): 130A
Tessier, C.; Prigent Tessier, A.; Ferguson Gottschall, S.; Gibori, G. 1999: PRL and TGFbeta1 play opposite roles in the regulation of apoptosis in the rat decidua. Biology of Reproduction 60(Suppl 1): 218-219
Pathak, M.K.; Dhawan, D.; Lindner, D.; Borden, E.; Farver, C.; Yi, T. 2003: PRL family phosphatases are inhibited by pentamidine in its anti-cancer action. Proceedings of the American Association for Cancer Research Annual Meeting 44: 134
Osborne, S.A.; Tonissen, K.F. 2002: PRL-TK induction can cause misinterpretation of gene promoter activity. Biotechniques 33(6): 1240-1242
Davies, S.J.C.; Lennard, M.S.; Eayrs, S.; Pratt, P. 2003: PRN Prescribing in psychiatric inpatients An important factor in pharmacokinetic drug interactions?. Journal of Psychopharmacology 17(Suppl 3): A42
Townsend, K.P.; Obregon, D.; Quadros, A.; Patel, N.; Volmar, C.; Paris, D.; Mullan, M. 2002: Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Annals of the new York Academy of Sciences 977: 65-76
Franti, M.; O'neill, T.J.; Burton, D.R.; Maddon, P.J.; Olson, W.C.; Poignard, P. 2001: PRO 542 has a profound impact on HIV-1 replication in the hu-PBL-SCID mouse model. Journal of Human Virology 4(3): 142
Orlova, M.; Ketas, T.J.; Frank, I.; Sullivan, B.M.; Spenlehauer, C.; Nesin, M.; Olson, W.C.; Moore, J.P.; Pope, M. 2002: PRO 542, a novel HIV-1 entry inhibitor, prevents infection of T cells in trans by dendritic cell-associated virus. Journal of Human Virology 5(1): 90
Martin, S. 2000: PRO-DIAB-Study Study for prevention of type 1 diabetes during prediabetes using oral protease therapy. Diabetes Research and Clinical Practice 50(Suppl 1): S92
Granja, F.; Santarosa, P.L.; Dias, M.M.; Pereira, J.A.; Muscelli, E.; Ward, L.S. 2002: PRO115GLN mutation in peroxisome-proliferator-activated receptor gamma2 and G972R insulin receptor substrate 1 receptor gene polymorphism in insulin resistant Brazilian. International Journal of Obesity 26(Suppl 1): S121
Furlan, A.J.; Higashida, R.; Wechsler, L.; Schulz, G. 1999: PROACT II Recombinant prourokinase in acute cerebral thromboembolism, initial trial results the PROACT II Investigators. Stroke 30(1): 234
Kim, H.K.; Rao, P.N.; Cessac, J.W.; Simmons, A.M. 2004: Process for Preparing 17alpha-Acetoxy-11beta- -21-Methoxy-19-Norp Regna-4,9-Diene-3,20-Dione, Intermediates Useful in the Process , and Processes for Preparing Such Intermediates. Official Gazette of the United States Patent and Trademark Office Patents 1284(4)
Sella Tavor, O.; Wool, A.; Smilansky, Z. 2002: PROCSY PROtein Characterization SYstem. Molecular and Cellular Proteomics 1(9): 716
Jacquet, H.; Raux, G.; Thibaut, F.; Hecketsweiler, B.; Houy, E.; Demilly, C.; Haouzir, S.; Allio, G.; Drouin, V.; Bou, J.; Petit, M.; Campion, D.; Frebourg, T. 2002: PRODH mutations and hyperprolinemia in schizophrenic patients. American Journal of Human Genetics 71(4 Suppl): 470
O'connell, J.R. 2000: PROFILER A program to compute cumulative probability profiles with applications to pedigree analysis. American Journal of Human Genetics 67(4 Suppl 2): 328
Engehausen, D.G.; Schroff, K.M. 1999: PROGINS polymorphism of the human progesterone receptor gene is increased in female offspring with maternal exposure to Diethylstilbestrol. Anticancer Research 19(6D): 5702-5703
Janscha, J.L.; Karth, A.; Li, P.L.; Zou, A.P. 2004: Prolyl Hydroxylase-Mediated Regulation of Hypoxia-Inducible Factor -1a in Renal Medullary cells. FASEB Journal 18(4-5): Abstract 471
Lanteri Minet, M.; Pradalier, A.; Lucas, C.; Geraud, G. 2003: PROMISE study The quality of life results. Cephalalgia 23(7): 712
Ginard, J.X.; Yackinous, C. 1999: PROP taster status and sensitivity to, and linking for fat. FASEB Journal 13(4 Part 1): A226
Mcduffie, J.R.; Uwaifo, G.I.; Fallon, E.; Rolls, B.; Yanovski, J.A. 2002: PROP taster status of obese adolescents is related to adiposity but not to hedonic ratings of puddings varying in fat content. International Journal of Obesity 26(Suppl 1): S131
Yackinous, C.A.; Guinard, J.X. 2000: PROP taster status, olfactory and tactile sensitivities, fat perception and dietary intake. FASEB Journal 14(4): A301
Delwiche, J.; Breslin, P. 2000: PROP tasting and sensitivity to other bitters. Abstracts of Papers American Chemical Society 219(1-2): AGFD 120
Cogan, J.D.; Phillips, J.A.; Carneal, J.L.; Hedges, L.K.; Doyle, D.A. 1999: PROP1 gene analysis in familial and sporadic CPHD. American Journal of Human Genetics 65(4): A145
Layman, L.C.; Cogan, J.D.; Carneal, J.; Layman, K.L.; Yu, D.V.; Kale, S.; Phillips, J.A.IIi 1999: PROP1 gene mutation analysis in patients with idiopathic hypogonadotropic hypogonadism. American Journal of Human Genetics 65(4): A474
Boettner, A.; Keller, E.; Kratzsch, J.; Weigel, J.; Keller, A.; Blum, W.F.; Kiess, W.; Pfaeffle, R. 2004: PROP1 mutations cause progressive failure of anterior pituitary function including ACTH deficiency. Growth Hormone and IGF Research 14(2): 145-146
Parks, J.S.; Brown, M.R.; Oltarzewski, M.; Lenartowska, I. 2000: PROP1 mutations in children with isolated deficiency of growth hormone. Pediatric Research 47(4 Part 2): 137A
Fernandez Ricaud, L.F.; Warringer, J.; Erikson, E.; Pylvanainen, I.; Nerman, O.; Blomberg, A. 2003: PROPHECY-a database with standardized high precision quantitative phenotypic information of yeast deletion strains. Yeast 20(Suppl 1): S343
Wilson, H.L.; Wong, A.C.C.; Tse, W.Y.; Mcdermid, H.E. 2000: PROSAP2 A candidate gene for neurological abnormalities in the 22q13 deletion syndrome. American Journal of Human Genetics 67(4 Suppl 2): 376
Rahman, M.A.; Dey, P.C. 2003: PROSHIKAs aquaculture extension approaches for sustainable rural development in Bangladesh. Phillips, Bruce , Reprint Author, Megrey, Bernard A, Zhou, Y Proceedings of the Third World Fisheries Congress: Feeding the world with fish in the next millenium - the balance between production and environment: 521-528
Hernandez Nazara, Z.; Amorim, M.; Else, C.; Svegliati Baroni, G.; Greenwel, P.; Rojkind, M. 2004: Proteasomal Degradation of Ski is Essential for Acetaldehyde-Dependent Up-Regulation of Alpha 2 Collagen Mrna in Hepatic Stellate cells. FASEB Journal 18(4-5): Abstract 623
PoojaVerma; AjeetSingh; HarmeetKaur; ManojMajee 2010: PROTEIN L-ISOASPARTYL METHYLTRANSFERASE1 from chickpea mitigates oxidative stress-induced growth inhibition of Escherichia coli. Planta 1(2): 329-336
Ritz, M.C.; Gallegos, R.; Canham, M.B.; Eskalai, M.; George, F.R. 2002: PROVANT Wound-Closure System accelerates closure of pressure wounds in a randomized, double-blind, placebo-controlled trial. Annals of the new York Academy of Sciences 961: 356-359
Lawton, A. 2002: PROfusion A broad-based proteomics platform. British Journal of Pharmacology 135(Proceedings Suppl): 144P
Hale, S.P. 1999: PROfusions Genetically tagged proteins for in-vitro evolution and selection. FASEB Journal 13(7): A1479
Prusiner, S.B.; Tremblay, P.; Moore, R.; Westaway, D.; Hood, L.E.; Lee, I. 2001: PRP-like gene. Official Gazette of the United States Patent and Trademark Office Patents 1249(3)
Furukawa, Y.; Morishita, F.; Matsushima, O. 2000: PRQFVamide activates two types of K+ currents in Aplysia neurons. Comparative Biochemistry and Physiology Part A Molecular and Integrative Physiology 127A(3): 373
Furukawa, Y.; Morishita, F.; Matsushima, O. 2000: PRQFVamide activates two types of receptors in Aplysia neurons. Zoological Science 17: 103
Dewey, C. 2000: PRRS in North America, Latin America, and Asia. Veterinary Research 31(1): 84-85
Sur, J.H.; Doster, A.R.; Galeota, J.; Wills, R.W.; Osorio, F.A. 2000: PRRSV Study of in vivo cell tropism and virus-induced apoptosis by in situ detection techniques. Veterinary Research 31(1): 58-59
Van Nieuwstadt, A.P.; Langeveld, J.; Meulenberg, J. 2002: PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays. Official Gazette of the United States Patent and Trademark Office Patents 1265(3)
Meulenberg, J.J. 2000: PRRSV, the virus. Veterinary Research 31(1): 11-21
Nauwynck, H.; Duan, X.; Pensaert, M. 2000: PRRSV-macrophage interaction and putative receptors. Veterinary Research 31(1): 22
Eriksson, P.; Thomas, L.R.; Thorburn, A.; Stillman, D.J. 2004: PRS yeast vectors with a LYS2 marker. Biotechniques 36(2): 212-213
D'angelo, A.; Andre, A.; Aglio, V.; Olivieri, S.; Garzia, L.; Arrigoni, G.; Lanzi, R.; Ballabio, A.; Zollo, M. 2002: PRUNE and NM23 protein interaction Possible implications in Neuroblastoma. European Journal of Human Genetics 10(Suppl 1): 111-112
Caruccio, L.; Walkovich, K.; Bettinotti, M.; Stroncek, D. 2002: PRV-1 Polymorphisms Correlation between High Frequency Single Nucleotide Substitutions and Neutrophil Surface Protein Expression. Blood 100(11): Abstract No. 259
Caruccio, L.; Bettinotti, M.; Fraser, E.; Director Myska, A.; Arthur, D.C.; Stroncek, D. 2003: PRV-1 and NB1 are alleles of a single gene, CD177, at region 19q132 and PRV-1 is the most common allele in a normal population. Blood 102(11): 661a
Pahl, H. 2004: PRV-1 gene and the use thereof. Official Gazette of the United States Patent and Trademark Office Patents 1279(1)
Griesshammer, M.; Klippel, S.; Mohr, U.; Strunck, E.; Heimpel, H.; Pahl, H.L. 2003: PRV-1 mRNA expression disriminates two types of Essential Thrombocythemia and can predict transition to polycythemia vera. Blood 102(11): 659a
Coch, C.; Bartels, K.; Buchkremer, S.; Hublitz, P.; Pahl, H.L. 2002: PRV-1/NB1/CD177 Physically Interacts with the Growth Regulatory Proteoglycan Decorin. Blood 100(11): Abstract No. 2307
Macleod, K. 1999: pRb and E2f-1 in mouse development and tumorigenesis. Current Opinion in Genetics and Development 9(1): 31-39
Tiwari, S.; Orr, S.; Thomas, N.S.B. 1999: PRb in mobilized CD34+ haemopoietic progenitor cells is phosphorylated on specific sites before the transition from G0 to G1A. British Journal of Haematology 105(Suppl 1): 104
Bertino, J.R.; Li, W.W.; Fan, J.; Schnieders, B.; Banerjee, D. 1999: PRb/E2F and drug resistance. Proceedings of the American Association for Cancer Research Annual Meeting 40: 771
Pucci, B.; Masciullo, V.; Claudio, P.P.; Bellincampi, L.; Khalili, K.; Melino, G.; Giordano, A. 2001: PRb2/p130 promotes radiation-induced apoptosis by Bcl-2 downregulation and p73 upregulation. Proceedings of the American Association for Cancer Research Annual Meeting 42: 738
Russo, G.; Claudio, P.P.; Del Core, F.; Mariano, C.; Giordano, A. 2003: PRb2/p130 target genes in human lung cancer cells identified by microarray analysis. Analytical Cellular Pathology 25(5-6): 219-220
Xie, Q.H.; Genin, A.; Choi, R.C.Y.; Peng, H.B.; Massoulie, J.; Tsim, K.W.K. 2004: PRiMA, the membrane anchor of acetylcholinesterase in the brain Characterization and function. Journal of Neurochemistry 88(Suppl 1): 85
Tsuyama, M.; Takemiya, A.; Kobayashi, Y. 2001: PS II down regulation as affected by the maximal activity of photorespiration in leaves of C3 plants. Photosynthesis Research 69(1-3): 172
Miura, H.; Yamato, Y.; Hamano, M.; Yamazaki, H. 2001: PS priming to improve emergence of garland chrysanthemum, chrysanthemum coronarium. HortScience 36(3): 582-583
Sun, K.; Welniak, L.A.; Wilkins, D.; Panoskaltsis Mortari, A.; Blazar, B.R.; Sayers, T.J.; Murphy, W.J. 2003: PS-341 administration inhibits acute graft-versus-host disease and preserves graft-versus-tumor after allogeneic BMT in advanced tumor- bearing mice. Blood 102(11): 192a
Pink, M.M.; Pien, C.S.; Worland, P.; Adams, J.; Kauffman, M.G. 2002: PS-341 enhances chemotherapeutic effect in human xenograft models. Proceedings of the American Association for Cancer Research Annual Meeting 43: 158
Camp, E.R.; Mackay, S.; Minnich, D.; Li, J.; Brank, A.; Lind, D.S.; Moldawer, L.L.; Hochwald, S.N. 2003: PS-341 enhances sensitivity of human gastric cancer to 5-FU and CPT-11 chemotherapy. Proceedings of the American Association for Cancer Research Annual Meeting 44: 741
Adams, J. 2003: PS-341, a potent and selective inhibitor of the proteasome. Toxicologic Pathology 31(1): 146-147
Adams, J. 2001: PS-341, a proteasome inhibitor for cancer treatment. Abstracts of Papers American Chemical Society 222(1-2): MEDI157
Qu, J.; Bloxham, D.M.; Sampson, C.; Lucy, J.A. 1999: PS-mediated adhesion of T cells to endothelial cells. Biochemical Society Transactions 27(3): A108
Koo, E.H.; Soriano, S.; Kang, D.E. 2002: PS1 interacts with and facilitates beta-catenin turnover. Israel, A , Reprint Author, DeStrooper, B, Checler, F, Christen, Y Notch from neurodevelopment to neurodegeneration: Keeping the fate: 119-129
Koo, J.; Chung, Y.; Park, M.; Park, S.; Chang, H. 2000: PS2 expression in gastric cancer. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1393
Chevallier, N.; Koo, E.H. 1999: PS2 partially rescues PS1 deficiency in APP processing. Society for Neuroscience Abstracts 25(1-2): 1856
Sonneveld, P.; Van Oostrum, N.H.M.; Schoester, M.; Van Oosterhoud, S. 2003: PS341 and the histone deacetylase inhibitor LAQ824 sensitize Melphalan resistant multiple myeloma cells to Melphalan. Blood 102(11): 189a-190a
Hernandez Ilizaliturri, F.J.; Kotowski, A.; Czuczman, M.S. 2003: PS341 inhibits cell proliferation, induces apoptosis of and enhances the biological effects of rituximab on non-Hodgkins lymphoma cell lines and lymphoma xenografts. Blood 102(11): 903a
Spike, E.; Brown, D.; Lord, E. 2001: PSA ELISA Immunology and the screening, treatment, and ethics of prostate cancer. FASEB Journal 15(4): A303
Morgan, M.; O'rourke, D.; Jasani, B.; Varma, M. 2003: PSA and PSAP immunoreactivity in the intraprostatic ejaculatory duct epithelium A potential pitfall in the diagnosis of prostate cancer in needle biopsies. Journal of Pathology 201(Suppl): 26A
Thelen, P.; Wuttke, W.; Zoeller, G.; Ringert, R.H.rmann 2003: PSA and VEGF expression in LNCAP prostate cancer cells is affected differently by various phyto-estrogens. Journal of Urology 169(4 Suppl): 157
Carter, B.; Metter, J.; Wright, J.; Landis, P.; Walsh, P.C. 2003: PSA and all cause mortality Results from the Baltimore Longitudinal Study of Aging. Journal of Urology 169(4 Suppl): 367-368
Arruda, H.Oliveira.de.; Vieira Filho, J.P.B.; Ortiz, V.; Srougi, M. 2003: PSA and anthropometric measurements among Amazon Indians: an evaluation of the Parkatejê community. Revista de Saude Publica 37(5): 624-628
Fowke,J.H.; Matthews,C.E. 2010: PSA and body composition by dual X-ray absorptiometry in NHANES. Prostate: 2, 120-125
Kurek, R.; Nunez, G.; Aumueller, G.; Tunn, U.; Renneberg, H. 2000: PSA and human kallikrein 2 RT-PCR in peripheral blood of prostate cancer patients. European Urology 37(Suppl 2): 117
Kurek, R.; Nunez, G.; Aumueller, G.; Tunn, U.W.; Renneberg, H. 2000: PSA and human kallikrein 2 RT-PCR in prostate cancer patients. Journal of Urology 163(4 Suppl): 189
Grivegnee, Andre Robert 2003: PSA and oriented work-up algorithm for prostate cancer detection. Proceedings of the American Association for Cancer Research Annual Meeting 44: 566-567
Sakr, W.A.; Grignon, D.; Che, M.; Kolizeras, K.; Andea, A.; Powell, I.J.; Cher, M.L.; Pontes, J.E.son 2004: PSA and pathological parameters of needle biopsy and radical prostatectomy specimens across the age spectrum of African American and caucasian men An analysis of 3049 BX and 1862 RPS. Journal of Urology 171(4 Suppl): 313
Kulpa, J.; Rychlik, U.; Wojcik, E.; Nowak Sadzikowska, J. 2003: PSA and testosterone levels in prostate cancer patients after radical radiotherapy. Tumor Biology 24(Suppl 1): 71
Schroder, F.H.; Van Der Cruijsen Koeter, I.; Vis, A.; Van Der Kwast, T.; Kranse, R. 2000: PSA based early detection of prostate cancer Validation of screening without rectal examination. Journal of Urology 163(4 Suppl): 89
Steiner, H.; Berger, A.; Spranger, R.; Hager, M.; Moser, P.; Horninger, W.; Bartsch, G. 2003: PSA based screening has significant impact on prostate cancer volume. Journal of Urology 169(4 Suppl): 427
Frazier, A.J.; Kaufman, N.; Siefer, J.R.; Zuniga, C.; Cher, M.; Ahmad, F.; Ben Josef, E.; Lutz, M.; Stuppler, S.; Forman, J.D. 2001: PSA biochemical control and risk of erectile dysfunction for young men undergoing prostate brachytherapy. International Journal of Radiation Oncology Biology Physics 51(3 Suppl 1): 288
Critz, F.; Williams, W.H.; Levinson, K.; Holladay, C.; Benton, J.; Griffin, V.; Hollady, D. 1999: PSA bounce following radioactive seed implantation for prostate cancer. Journal of Urology 161(4 Suppl): 336
Salgado, J.; Martinez, J.; Leon, C.; Muros, M. 1999: PSA concentration in pregnant women. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S349
Lujan, M.; Paez, A.; Llanes, L.; Berenguer, A. 2000: PSA density Is there still a role for this parameter when screening for prostate cancer?. European Urology 38(4): 506
Jeon, H.S.; Kowal, J.; Kwak, Y.S. 1999: PSA detection of prostate cancer in White American, Black American and Asian men. Prostate 38(4): 327-328
Choo, R.; Klotz, L.; Deboer, G.; Danjoux, C.; Morton, G. 2003: PSA doubling time is quite variable in untreated, clinically localized, low to intermediate grade, prostate adenocarcinoma. EJC Suppls 1(5): S327
Nazari, S.; Wolter, S.; Kreutzer, N.; Haupt, G.; Engelmann, U. 2003: PSA examination Whole blood quick test versus standard serum test in 1034 samples. European Urology Suppls 2(1): 185
Schroder, F.H. 2002: PSA in clinical practice Use and misuse Where do we stand. International Journal of Cancer Suppl (13): 46
Stephenson, A.J.; Aprikian, A.G.; Souhami, L.; Begin, L.R.; Behlouli, H.; Jacobson, A.I.; Tanguay, S. 2001: PSA is a poor predictor of disease-progression in watchful waiting patients with localized prostate cancer. Journal of Urology 165(5 Suppl): 352-353
Roehrborn, C.G.; Boyle, P.; Nickel, J.C.rtis 2003: PSA is a significant predictor of objective parameters in men at risk for BPH progression. Journal of Urology 169(4 Suppl): 364-365
Tunc, M.; Sanli, O.; Mirzazad, M.; Kandirali, E.; Oktar, T.; Ozsoy, C. 2004: PSA is not a predictive factor for estimating the natural course of high grade prostatic intraepithelial neoplasia. European Urology Suppls 3(2): 66
Fuss, M.; Cavanaugh, S.; Voeltz, L.; Fuller, C.; Salter, B.; Herman, T. 2003: PSA kinetics following IMRT for prostate cancer The impact of daily stereotactic ultrasound targeting. International Journal of Radiation Oncology Biology Physics 57(2 Suppl): S390-S391
Fuss, M.; Cavanaugh, S.; Salter, B.; Voeltz, L.; Pollock, B.; Bradshaw, P.; Herman, T. 2003: PSA kinetics following intensity-modulated radiotherapy for prostate cancer The impact of daily stereotactic ultrasound targeting. European Urology Suppls 2(1): 132
Vertocnik, A.; Stock, R.; Calligy, J.; Stone, N.N. 2003: PSA kinetics in low-risk patients with permanent radioactive seed implantation. International Journal of Radiation Oncology Biology Physics 57(2 Suppl): S401-S402
Evans, C.; Doyle, C.A.; Ranhosky, A. 2001: PSA levels and occurrence of prostate cancer during long-term study of treatment with tamsulosin for BPH. Journal of Urology 165(5 Suppl): 382
Valeri, A.; Cormier, L.; Cancel Tassin, G.; Giordanella, M.; Kuntz, M.; Moineau, M.P.; Berthon, P.; Mangin, P.; Cussenot, O.; Morin, J.; Fournier, G. 2002: PSA levels in unaffected first degree relatives of prostate cancer patients are higher than in men without family history of the disease. European Urology Suppls 1(1): 75
Zarghami, N.Z.; Diamandis, E.P.D.; Grass, L. 1999: PSA mRNA expression during menstrual cycle is upregulated by progesterone. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S159
Zambon, C.F.; Gelmini, S.; Orlando, C.; Mazza, S.; Basso, D.; Navaglia, F.; Prayer Galetti, T.; Piva, M.G.; Pagano, F.; Plebani, M. 2001: PSA mRNA real time quantification in blood A promising tool for prostate cancer diagnosis?. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S163
Gretzer, M.B.; Partin, A.W. 2003: PSA markers in prostate cancer detection. Urologic Clinics of North America 30(4): 677-686
Abi, M.M.; Manunta, A.; Patard, J.J.; Guille, F.; Lhorfi, H.; Morin, G.; Moudouni, S.; Lobel, B. 2002: PSA measurement and referral to the urological clinic in the catchment area of a French teaching hospital. European Urology Suppls 1(1): 77
Fitzpatrick, J.M. 2004: PSA measurement in the treatment of BPH. Bju International 93(Suppl 1): 2-4
Reissigl, A.; Remzi, M.; Wiunig, C.; Dobrovits, M.; Zlotta, A.; Ravery, V.; Hammerer, P.; Dobronski, P.; Kaisary, A.; Marberger, M.; Djavan, B. 2004: PSA molecular forms and indices for early detection of prostate cancer in men with total PSA between 20 and 40 ng/ml Final results of the EPCD Study. European Urology Suppls 3(2): 35
Deger, S.; Boehmer, D.; Roigas, J.; Tuerk, I.; Schnorr, D.; Budach, V.; Loening, S.A. 2000: PSA nadir after high dose rate brachytherapy of prostate cancer. Journal of Urology 163(4 Suppl): 283
Critz, F.A.; Williams, W.H.; Holladay, C.T.; Benton, J.B.; Schnelland, F.J.; Shrake, P.D. 2000: PSA normalization following radiotherapy of prostate cancer An analysis of PSA in 649 disease free men. International Journal of Radiation Oncology Biology Physics 48(3 Suppl): 313
Pang, S.; Belldegrun, A.S. 2000: PSA positive regulating sequences and uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1237(5)
Simone, N.L.; Remaley, A.T.; Petricoin, E.F.; Glickman, J.W.; Bonner, R.; Emmert Buck, M.R.; Fleischer, T.A.; Liotta, L.A. 1999: PSA quantitation in prostate cancer tissue cells procured by laser capture microdissection. Proceedings of the American Association for Cancer Research Annual Meeting 40: 411
Aidonopoulos, H.T.; Sofi, C.; Adamos, I.; Ioannidis, A.; Aidonopoulos, T.H.; Aslam, D. 2000: PSA recording and prostate cancer tracing in a special group of population. European Urology 38(4): 505-506
Hoh, I.M.; Winkler, M.H.; Khan, F.A.; Caldwell, C.; Constantinou, J.; Kaisary, A.V.; Gillat, D.A. 2003: PSA recurrence free survival by clinical stage, PSA and biopsy gleason grade A multicentre audit of radical prostatectomy. Scandinavian Journal of Urology and Nephrology 37(Suppl 214): 13
Sovak, M.; Hajduch, M.; Masner, O.; Endlicherova, P.; Prokop, J. 2003: PSA rising syndrome Resorption, synergism and potential utility of t-Resveratrol, its glycon piceid and Curcumin. Proceedings of the American Association for Cancer Research Annual Meeting 44: 942
Fossa, S. 2002: PSA screening Justification of the Norwegian policy. International Journal of Cancer Suppl (13): 46-47